|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions |
ISO |
Timolol binds to and results in decreased activity of ADRB1 protein; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:11436944 PMID:15060759 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
[Timolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Timolol binds to and results in decreased activity of ADRB2 protein |
CTD |
PMID:11436944 PMID:17925438 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Aoc1 |
amine oxidase, copper containing 1 |
multiple interactions |
EXP |
Timolol inhibits the reaction [Epinephrine results in increased activity of AOC1 protein] |
CTD |
PMID:2860926 |
|
NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects response to substance |
ISO |
CYP2D6 gene SNP affects the susceptibility to Timolol |
CTD |
PMID:19284319 PMID:20925579 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein; RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK1 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11914123 PMID:18977218 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein; RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK3 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11914123 PMID:18977218 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Rgs3 |
regulator of G-protein signaling 3 |
multiple interactions |
ISO |
RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:18977218 |
|
NCBI chr 5:76,022,038...76,161,895
Ensembl chr 5:76,022,001...76,161,894
|
|
G |
Rgs4 |
regulator of G-protein signaling 4 |
multiple interactions |
ISO |
RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:18977218 |
|
NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068
|
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP |
platelet-activating factor increases expression of Tnf protein in portal stenosis rat plasma |
RGD |
PMID:10452877 |
RGD:38508900 |
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions increases activity |
ISO |
[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; CGP 20712A inhibits the reaction [[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [Acebutolol results in increased activity of ADRB1 protein] |
CTD |
PMID:12761341 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
[Acebutolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:17925438 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
Acebutolol results in increased expression of FOS mRNA |
CTD |
PMID:12730611 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:17925438 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:17925438 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Ren |
renin |
decreases activity |
ISO EXP |
Acebutolol results in decreased activity of REN protein |
CTD |
PMID:6110712 PMID:6118215 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions increases phosphorylation increases activity |
ISO |
[Alprenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Alprenolol binds to and results in decreased activity of ADRB1 protein; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Alprenolol inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Alprenolol promotes the reaction [ADRB1 protein binds to ARRB1 protein]; Alprenolol promotes the reaction [ADRB1 protein binds to ARRB2 protein]; Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; CGP 20712A affects the reaction [Alprenolol results in increased activity of ADRB1 protein]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] [Alprenolol results in increased phosphorylation of ADRB1 protein] which results in increased phosphorylation of EGFR protein; Alprenolol results in increased phosphorylation of ADRB1 protein |
CTD |
PMID:12761341 PMID:14730417 PMID:15060759 PMID:18787115 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
[Alprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Alprenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Alprenolol co-treated with ADRB2 protein] results in increased expression of GNAS protein; Alprenolol inhibits the reaction [cyanopindolol binds to ADRB2 protein] Alprenolol inhibits the reaction [ADRB2 results in decreased susceptibility to Histamine]; Alprenolol inhibits the reaction [ADRB2 results in increased expression of GRK2 protein] |
CTD |
PMID:10455254 PMID:12198331 PMID:14730417 PMID:17925438 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
ISO |
[Alprenolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Alprenolol binds to and results in increased activity of ADRB3 protein; Alprenolol inhibits the reaction [cyanopindolol binds to ADRB3 protein] |
CTD |
PMID:14730417 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
[Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR125A mRNA; [Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR125B-1 mRNA; [Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR150 mRNA; [Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR214 mRNA; Alprenolol promotes the reaction [ADRB1 protein binds to ARRB1 protein]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:18787115 PMID:24334028 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
Alprenolol promotes the reaction [ADRB1 protein binds to ARRB2 protein]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:18787115 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Cs |
citrate synthase |
multiple interactions increases activity |
EXP |
[POMC protein co-treated with Alprenolol] results in increased activity of CS protein Alprenolol results in increased activity of CS protein |
CTD |
PMID:6274165 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] [Alprenolol results in increased phosphorylation of ADRB1 protein] which results in increased phosphorylation of EGFR protein |
CTD |
PMID:18787115 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions |
ISO |
[Alprenolol co-treated with ADRB2 protein] results in increased expression of GNAS protein |
CTD |
PMID:10455254 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
Alprenolol inhibits the reaction [ADRB2 results in increased expression of GRK2 protein] |
CTD |
PMID:12198331 |
|
NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions |
ISO |
HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] |
CTD |
PMID:18787115 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
multiple interactions |
ISO |
[Alprenolol co-treated with Cocaine] affects the reaction [HTR2A protein results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine] |
CTD |
PMID:8392199 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
[Alprenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:17925438 PMID:18787115 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
[Alprenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:17925438 PMID:18787115 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mir125a |
microRNA 125a |
multiple interactions increases expression |
ISO |
[Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR125A mRNA Alprenolol results in increased expression of MIR125A mRNA |
CTD |
PMID:24334028 |
|
NCBI chr 1:58,677,626...58,677,710
Ensembl chr 1:58,677,626...58,677,710
|
|
G |
Mir125b1 |
microRNA 125b-1 |
multiple interactions increases expression |
ISO |
[Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR125B-1 mRNA Alprenolol results in increased expression of MIR125B-1 mRNA |
CTD |
PMID:24334028 |
|
NCBI chr 8:41,952,966...41,953,052
Ensembl chr 8:41,952,966...41,953,052
|
|
G |
Mir150 |
microRNA 150 |
multiple interactions increases expression |
ISO |
[Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR150 mRNA Alprenolol results in increased expression of MIR150 mRNA |
CTD |
PMID:24334028 |
|
NCBI chr 1:95,605,024...95,605,108
Ensembl chr 1:95,605,024...95,605,108
|
|
G |
Mir214 |
microRNA 214 |
increases expression multiple interactions |
ISO |
Alprenolol results in increased expression of MIR214 mRNA [Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR214 mRNA |
CTD |
PMID:24334028 |
|
NCBI chr13:74,588,374...74,588,481
Ensembl chr13:74,588,372...74,588,481
|
|
G |
Nppa |
natriuretic peptide A |
increases expression |
ISO |
Alprenolol results in increased expression of NPPA mRNA |
CTD |
PMID:12721106 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions |
ISO |
Alprenolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein] |
CTD |
PMID:10353628 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions |
EXP |
[POMC protein co-treated with Alprenolol] results in increased activity of CS protein |
CTD |
PMID:6274165 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ren |
renin |
multiple interactions decreases expression |
ISO |
Alprenolol inhibits the reaction [Hydralazine results in increased expression of REN protein] Alprenolol results in decreased expression of REN protein |
CTD |
PMID:923630 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Alprenolol inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases activity decreases expression |
ISO |
Asenapine results in decreased activity of CYP1A2 protein Asenapine results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:32941854 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases activity |
ISO |
Atenolol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Atenolol results in decreased activity of ABCB11 protein |
CTD |
PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Adra2a |
adrenoceptor alpha 2A |
affects response to substance |
ISO |
ADRA2A gene SNP affects the susceptibility to Atenolol |
CTD |
PMID:15614026 |
|
NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
decreases activity multiple interactions affects binding affects response to substance decreases expression |
ISO EXP |
Atenolol results in decreased activity of ADRB1 protein Atenolol binds to and results in decreased activity of ADRB1 protein; Atenolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Atenolol inhibits the reaction [Dihydroalprenolol binds to ADRB1 protein] Atenolol binds to ADRB1 protein [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased susceptibility to Nicotine; [Atenolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; Atenolol binds to and results in decreased activity of ADRB1 protein; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Atenolol inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Atenolol inhibits the reaction [Isoproterenol results in increased activity of ADRB1 protein] ADRB1 protein polymorphism affects the susceptibility to Atenolol Atenolol results in decreased expression of ADRB1 mRNA |
CTD |
PMID:1389726 PMID:2462161 PMID:2897299 PMID:8102213 PMID:8386603 PMID:9593075 PMID:10372227 PMID:10894789 PMID:11425575 PMID:11483288 PMID:12022239 PMID:12761341 PMID:14730417 PMID:15060759 PMID:17003101 PMID:17369603 PMID:17628611 PMID:22192668 More...
|
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
increases expression affects binding multiple interactions |
ISO EXP |
Atenolol results in increased expression of ADRB2 protein Atenolol binds to ADRB2 protein Atenolol binds to and results in decreased activity of ADRB2 protein; Atenolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Atenolol inhibits the reaction [Dihydroalprenolol binds to ADRB2 protein] [Atenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Atenolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; Atenolol binds to and results in decreased activity of ADRB2 protein; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; Atenolol inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Atenolol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; Atenolol inhibits the reaction [Isoproterenol binds to and results in increased activity of ADRB2 protein]; Atenolol inhibits the reaction [Terbutaline binds to and results in increased activity of ADRB2 protein] |
CTD |
PMID:2462161 PMID:6093157 PMID:9593075 PMID:11425575 PMID:11483288 PMID:12920204 PMID:14730417 PMID:17925438 More...
|
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [cyanopindolol binds to ADRB3 protein] |
CTD |
PMID:14730417 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Agt |
angiotensinogen |
affects response to substance decreases expression |
ISO |
AGT gene SNP affects the susceptibility to Atenolol Atenolol results in decreased expression of AGT protein |
CTD |
PMID:14639093 PMID:14700505 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Amy2a3 |
amylase 2a3 |
multiple interactions |
EXP |
Atenolol inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein]; Atenolol inhibits the reaction [Cisplatin results in increased secretion of and results in increased activity of AMY1A protein]; Atenolol inhibits the reaction [Isoproterenol results in increased secretion of and results in increased activity of AMY1A protein]; Atenolol inhibits the reaction [Lithium Chloride results in increased secretion of and results in increased activity of AMY1A protein] |
CTD |
PMID:21173550 |
|
NCBI chr 2:201,317,916...201,326,487
Ensembl chr 2:201,317,920...201,326,532
|
|
G |
Apoa1 |
apolipoprotein A1 |
decreases expression |
ISO |
Atenolol results in decreased expression of APOA1 protein |
CTD |
PMID:2193493 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa2 |
apolipoprotein A2 |
decreases expression |
ISO |
Atenolol results in decreased expression of APOA2 protein |
CTD |
PMID:2193493 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Apob |
apolipoprotein B |
increases expression |
ISO |
Atenolol results in increased expression of APOB; Atenolol results in increased expression of APOB protein |
CTD |
PMID:1928808 PMID:2193493 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Atf1 |
activating transcription factor 1 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of ATF1 protein] |
CTD |
PMID:16671086 |
|
NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670
|
|
G |
B2m |
beta-2 microglobulin |
decreases expression |
ISO |
Atenolol results in decreased expression of B2M protein |
CTD |
PMID:2656332 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
affects response to substance |
ISO |
BDKRB2 exon polymorphism affects the susceptibility to Atenolol |
CTD |
PMID:12640257 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Cacna1c |
calcium voltage-gated channel subunit alpha1 C |
increases response to substance |
ISO |
CACNA1C gene polymorphism results in increased susceptibility to Atenolol |
CTD |
PMID:20031608 |
|
NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [Epinephrine results in increased activity of CASP3 protein] |
CTD |
PMID:10728402 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Atenolol inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]; Atenolol promotes the reaction [Quercetin inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]]; Atenolol promotes the reaction [Thyroxine results in decreased expression of CAT protein]; Quercetin promotes the reaction [Atenolol inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]] |
CTD |
PMID:2575990 PMID:22391854 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [Isoproterenol results in increased expression of CDK1 mRNA] |
CTD |
PMID:9593584 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:16671086 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Edn1 |
endothelin 1 |
affects response to substance |
ISO |
EDN1 gene polymorphism affects the susceptibility to Atenolol |
CTD |
PMID:15188945 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of EGFR protein] |
CTD |
PMID:16671086 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
Atenolol inhibits the reaction [Epinephrine results in increased expression of FAS protein] |
CTD |
PMID:10728402 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
Atenolol inhibits the reaction [Epinephrine results in increased expression of FASLG protein] |
CTD |
PMID:10728402 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
ISO |
Atenolol promotes the reaction [FKBP1B protein binds to RYR2 protein] |
CTD |
PMID:12743001 |
|
NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
decreases expression |
ISO |
Atenolol results in decreased expression of FKBP5 mRNA |
CTD |
PMID:19915711 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
Atenolol inhibits the reaction [Dopamine results in increased activity of G6PD protein]; Atenolol inhibits the reaction [Isoproterenol results in increased activity of G6PD protein] |
CTD |
PMID:1978808 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression |
EXP |
Atenolol results in increased expression of GJA1 protein |
CTD |
PMID:16448880 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gja4 |
gap junction protein, alpha 4 |
increases expression |
EXP |
Atenolol results in increased expression of GJA4 protein |
CTD |
PMID:16448880 |
|
NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
decreases expression |
ISO |
Atenolol results in decreased expression of GRK2 mRNA; Atenolol results in decreased expression of GRK2 protein |
CTD |
PMID:9788834 |
|
NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [Terbutaline results in increased expression of INS protein] |
CTD |
PMID:12795776 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Kcnj2 |
potassium inwardly-rectifying channel, subfamily J, member 2 |
affects response to substance |
ISO |
KCNJ2 gene affects the susceptibility to Atenolol |
CTD |
PMID:15028050 |
|
NCBI chr10:96,060,834...96,071,397
Ensembl chr10:96,060,821...96,071,445
|
|
G |
Kcnq1 |
potassium voltage-gated channel subfamily Q member 1 |
affects response to substance |
ISO |
KCNQ1 gene affects the susceptibility to Atenolol |
CTD |
PMID:15028050 |
|
NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
LIPC gene SNP affects the susceptibility to and affects the metabolism of Atenolol |
CTD |
PMID:23536766 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16671086 PMID:17003101 PMID:17925438 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:16671086 PMID:17003101 PMID:17925438 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [Carvedilol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Atenolol inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Atenolol inhibits the reaction [Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] |
CTD |
PMID:19439816 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppa |
natriuretic peptide A |
decreases expression |
ISO |
Atenolol results in decreased expression of NPPA protein |
CTD |
PMID:12866806 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions decreases expression increases expression |
EXP ISO |
[Atenolol co-treated with Doxazosin] results in decreased expression of NPPB mRNA; [Atenolol co-treated with Losartan co-treated with Doxazosin] results in decreased expression of NPPB mRNA Atenolol results in decreased expression of NPPB mRNA Atenolol results in increased expression of NPPB protein |
CTD |
PMID:15969258 PMID:18192850 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Pla2g4c |
phospholipase A2 group IVC |
multiple interactions |
ISO |
PLA2G4C gene SNP affects the susceptibility to and affects the metabolism of Atenolol |
CTD |
PMID:23536766 |
|
NCBI chr 1:74,237,714...74,275,757
Ensembl chr 1:74,236,211...74,274,656
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein] |
CTD |
PMID:17003101 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn5 |
protein tyrosine phosphatase, non-receptor type 5 |
multiple interactions |
EXP |
Atenolol inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein] |
CTD |
PMID:17623046 |
|
NCBI chr 1:97,620,638...97,681,186
Ensembl chr 1:97,620,642...97,679,882
|
|
G |
Ren |
renin |
multiple interactions decreases expression decreases activity |
ISO EXP |
[aliskiren co-treated with Atenolol] results in decreased activity of REN protein; [Dexamethasone co-treated with Nifedipine co-treated with Atenolol co-treated with Antihypertensive Agents] results in increased secretion of REN protein Atenolol results in decreased expression of REN protein Atenolol inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of REN protein]; Atenolol inhibits the reaction [2-hexynyladenosine-5'-N-ethylcarboxamide results in increased expression of REN protein] Atenolol results in decreased activity of REN protein |
CTD |
PMID:3142437 PMID:3333524 PMID:9300315 PMID:14639093 PMID:18957387 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Ryr2 |
ryanodine receptor 2 |
increases activity multiple interactions |
ISO |
Atenolol results in increased activity of RYR2 protein Atenolol promotes the reaction [FKBP1B protein binds to RYR2 protein] |
CTD |
PMID:12743001 |
|
NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142
|
|
G |
Slc19a1 |
solute carrier family 19 member 1 |
decreases expression |
ISO |
Atenolol results in decreased expression of SLC19A1 mRNA |
CTD |
PMID:19616087 |
|
NCBI chr20:11,584,410...11,602,429
Ensembl chr20:11,584,411...11,601,972
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
Atenolol inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc6a8 |
solute carrier family 6 member 8 |
decreases expression |
ISO |
Atenolol results in decreased expression of SLC6A8 mRNA |
CTD |
PMID:19915711 |
|
NCBI chr X:151,384,675...151,393,979
Ensembl chr X:151,384,675...151,393,979
|
|
G |
Slco4c1 |
solute carrier organic anion transporter family, member 4C1 |
increases expression |
ISO |
Atenolol results in increased expression of SLCO4C1 mRNA |
CTD |
PMID:19915711 |
|
NCBI chr 9:97,177,497...97,229,161
Ensembl chr 9:97,178,861...97,229,715
|
|
G |
Snora49 |
small nucleolar RNA, H/ACA box 49 |
increases expression |
ISO |
Atenolol results in increased expression of SNORA49 mRNA |
CTD |
PMID:19915711 |
|
NCBI chr12:45,970,884...45,971,016
Ensembl chr12:45,970,884...45,971,016
|
|
G |
Snrpn |
small nuclear ribonucleoprotein polypeptide N |
increases expression |
ISO |
Atenolol results in increased expression of SNRPN mRNA |
CTD |
PMID:19915711 |
|
NCBI chr 1:111,101,327...111,123,400
Ensembl chr 1:111,101,329...111,123,634
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO EXP |
Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD1 protein] Atenolol promotes the reaction [Thyroxine results in decreased expression of SOD1 protein] |
CTD |
PMID:2575990 PMID:11163531 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO EXP |
Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD2 protein] Atenolol inhibits the reaction [Thyroxine results in increased expression of SOD2 protein] |
CTD |
PMID:2575990 PMID:11163531 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
decreases response to substance |
ISO |
TRPA1 gene mutant form results in decreased susceptibility to Atenolol |
CTD |
PMID:29627347 |
|
NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
ISO |
Atenolol results in increased expression of TXN mRNA |
CTD |
PMID:19915711 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions affects binding |
EXP ISO |
Betaxolol affects the reaction [Cocaine affects the expression of ADRB1 protein]; Betaxolol inhibits the reaction [Cocaine affects the expression of ADRB1 protein] Betaxolol binds to ADRB1 protein Betaxolol binds to and results in decreased activity of ADRB1 protein |
CTD |
PMID:10372227 PMID:11436944 PMID:17513029 PMID:18596687 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
[Betaxolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Betaxolol binds to and results in decreased activity of ADRB2 protein |
CTD |
PMID:11436944 PMID:17925438 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Betaxolol affects the reaction [Cocaine affects the phosphorylation of CREB1 protein] |
CTD |
PMID:18596687 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
EXP |
Betaxolol affects the reaction [Cocaine affects the expression of CRH mRNA] |
CTD |
PMID:18596687 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Nppa |
natriuretic peptide A |
decreases expression |
EXP |
Betaxolol results in decreased expression of NPPA mRNA; Betaxolol results in decreased expression of NPPA protein |
CTD |
PMID:12693380 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
decreases expression |
EXP |
Betaxolol results in decreased expression of NPPB mRNA |
CTD |
PMID:12693380 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
decreases expression |
EXP |
bevantolol results in decreased expression of ADRB1 mRNA |
CTD |
PMID:17628611 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport multiple interactions |
ISO |
ABCB1 protein results in increased transport of Bisoprolol Bisoprolol inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; valspodar inhibits the reaction [ABCB1 protein results in increased transport of Bisoprolol] |
CTD |
PMID:16671962 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
decreases activity increases expression multiple interactions affects binding |
ISO EXP |
Bisoprolol results in decreased activity of ADRB1 protein Bisoprolol results in increased expression of ADRB1 mRNA [Bisoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; Bisoprolol binds to and results in decreased activity of ADRB1 protein; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Bisoprolol inhibits the reaction [cyanopindolol binds to ADRB1 protein] Bisoprolol binds to ADRB1 protein |
CTD |
PMID:1389726 PMID:2897299 PMID:10372227 PMID:11562432 PMID:12535855 PMID:14730417 PMID:15060759 PMID:17200720 PMID:20668454 More...
|
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions increases expression |
ISO EXP |
[Bisoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; Bisoprolol binds to and results in decreased activity of ADRB2 protein; Bisoprolol inhibits the reaction [cyanopindolol binds to ADRB2 protein] Bisoprolol results in increased expression of ADRB2 mRNA |
CTD |
PMID:14730417 PMID:17925438 PMID:20668454 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
ISO |
Bisoprolol inhibits the reaction [cyanopindolol binds to ADRB3 protein] |
CTD |
PMID:14730417 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Bisoprolol results in decreased expression of CCL2 protein |
CTD |
PMID:19840533 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Gnas |
GNAS complex locus |
increases expression |
EXP |
Bisoprolol results in increased expression of GNAS mRNA |
CTD |
PMID:20668454 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Il10 |
interleukin 10 |
increases expression |
ISO |
Bisoprolol results in increased expression of IL10 protein |
CTD |
PMID:19840533 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression |
ISO |
Bisoprolol results in decreased expression of IL1B protein |
CTD |
PMID:19840533 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
decreases expression |
ISO |
Bisoprolol results in decreased expression of IL6 protein |
CTD |
PMID:19840533 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
Bisoprolol inhibits the reaction [Terbutaline results in increased expression of INS protein] |
CTD |
PMID:12795776 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Prkca |
protein kinase C, alpha |
decreases expression |
EXP |
Bisoprolol results in decreased expression of PRKCA protein |
CTD |
PMID:20668454 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcd |
protein kinase C, delta |
decreases expression |
EXP |
Bisoprolol results in decreased expression of PRKCD protein |
CTD |
PMID:20668454 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
Bisoprolol inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Bisoprolol inhibits the reaction [SLC22A2 protein results in increased uptake of Metformin] |
CTD |
PMID:19740083 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression |
ISO |
Bisoprolol results in decreased expression of TNF protein |
CTD |
PMID:19840533 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
bopindolol results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
bopindolol inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions |
ISO |
Carteolol binds to and results in decreased activity of ADRB1 protein |
CTD |
PMID:11436944 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
Carteolol binds to and results in decreased activity of ADRB2 protein |
CTD |
PMID:11436944 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Arrb1 |
arrestin, beta 1 |
increases expression |
ISO |
Carteolol results in increased expression of ARRB1 protein |
CTD |
PMID:37120125 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Arrb2 |
arrestin, beta 2 |
increases expression |
ISO |
Carteolol results in increased expression of ARRB2 protein |
CTD |
PMID:37120125 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases expression |
ISO |
Carteolol results in increased expression of and results in increased phosphorylation of ATM protein Carteolol results in increased expression of ATM mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Cat |
catalase |
affects activity |
ISO |
Carteolol affects the activity of CAT protein |
CTD |
PMID:37120125 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl27 |
C-C motif chemokine ligand 27 |
increases expression |
ISO |
Carteolol results in increased expression of CCL27 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 5:56,941,402...56,948,511
Ensembl chr 5:56,941,402...56,948,506
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
affects expression |
ISO |
Carteolol affects the expression of CDKN1A mRNA |
CTD |
PMID:37120125 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases expression |
ISO |
Carteolol results in increased expression of CDKN2A mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Fahd1 |
fumarylacetoacetate hydrolase domain containing 1 |
affects expression |
ISO |
Carteolol affects the expression of FAHD1 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr10:13,873,539...13,874,978
Ensembl chr10:13,873,527...13,875,012
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
affects activity |
ISO |
Carteolol affects the activity of GPX1 protein |
CTD |
PMID:37120125 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation |
ISO |
Carteolol results in increased phosphorylation of H2AX protein |
CTD |
PMID:37120125 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hk2 |
hexokinase 2 |
affects expression |
ISO |
Carteolol affects the expression of HK2 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Il10 |
interleukin 10 |
increases expression |
ISO |
Carteolol results in increased expression of IL10 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
Carteolol results in increased expression of IL1A mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
Carteolol results in increased expression of IL6 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lmnb1 |
lamin B1 |
decreases expression |
ISO |
Carteolol results in decreased expression of LMNB1 protein |
CTD |
PMID:37120125 |
|
NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
affects localization |
ISO |
Carteolol affects the localization of MAP1LC3B protein |
CTD |
PMID:37120125 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Carteolol results in increased expression of and results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:37120125 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Carteolol results in increased expression of and results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:37120125 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
Carteolol results in decreased expression of MKI67 protein |
CTD |
PMID:37120125 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
affects expression |
ISO |
Carteolol affects the expression of MTOR protein |
CTD |
PMID:37120125 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nampt |
nicotinamide phosphoribosyltransferase |
affects expression |
ISO |
Carteolol affects the expression of NAMPT mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects expression |
ISO |
Carteolol affects the expression of NFE2L2 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression |
ISO |
Carteolol results in increased expression of NFKB1 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nox4 |
NADPH oxidase 4 |
increases expression |
ISO |
Carteolol results in increased expression of NOX4 protein |
CTD |
PMID:37120125 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
affects expression |
ISO |
Carteolol affects the expression of PARP1 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Sirt1 |
sirtuin 1 |
affects expression |
ISO |
Carteolol affects the expression of SIRT1 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sod1 |
superoxide dismutase 1 |
affects activity |
ISO |
Carteolol affects the activity of SOD1 protein |
CTD |
PMID:37120125 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
affects activity |
ISO |
Carteolol affects the activity of SOD2 protein |
CTD |
PMID:37120125 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
Carteolol results in increased expression of TGFB1 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
Carteolol results in increased expression of TNF mRNA |
CTD |
PMID:37120125 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
affects expression |
ISO |
Carteolol affects the expression of TP53 mRNA |
CTD |
PMID:37120125 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions decreases expression |
ISO |
Carvedilol inhibits the reaction [Albuterol results in increased expression of ABCB11 mRNA] Carvedilol results in decreased expression of ABCB11 protein |
CTD |
PMID:37632784 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases transport multiple interactions decreases activity |
ISO EXP |
ABCB1 protein results in increased transport of carvedilol [Cyclosporine results in decreased activity of ABCB1 protein] which results in increased uptake of carvedilol [carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]] which results in decreased susceptibility to Daunorubicin; [carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Doxorubicin]] which results in decreased susceptibility to Doxorubicin; [carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Paclitaxel]] which results in decreased susceptibility to Paclitaxel; [carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Vinblastine]] which results in decreased susceptibility to Vinblastine; [carvedilol results in decreased activity of ABCB1 protein] which results in increased susceptibility to Doxorubicin; [carvedilol results in decreased activity of ABCB1 protein] which results in increased uptake of fluorexon; carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Doxorubicin]; carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Paclitaxel]; carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Vinblastine]; valspodar inhibits the reaction [ABCB1 protein results in increased transport of carvedilol] |
CTD |
PMID:10571255 PMID:11895100 PMID:12708479 PMID:16671962 PMID:17609666 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
ISO |
Carvedilol results in decreased expression of ABCC2 protein |
CTD |
PMID:37632784 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
decreases expression |
ISO |
Carvedilol results in decreased expression of ABCC4 protein |
CTD |
PMID:37632784 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions |
EXP ISO |
carvedilol inhibits the reaction [Colchicine results in decreased activity of ACE protein] carvedilol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ACE mRNA] |
CTD |
PMID:15071347 PMID:18992766 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions decreases expression |
EXP |
Carvedilol inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]; Carvedilol inhibits the reaction [Ethanol results in increased expression of ACTA2 mRNA]; Carvedilol inhibits the reaction [Ethanol results in increased expression of ACTA2 protein] carvedilol results in decreased expression of ACTA2 protein |
CTD |
PMID:20403466 PMID:22413959 PMID:30254303 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actn4 |
actinin alpha 4 |
decreases expression |
EXP |
carvedilol results in decreased expression of ACTN4 protein |
CTD |
PMID:20403466 |
|
NCBI chr 1:84,182,783...84,251,867
Ensembl chr 1:84,182,788...84,251,847
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression |
ISO |
carvedilol results in decreased expression of ADIPOQ protein |
CTD |
PMID:19367012 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
multiple interactions decreases expression |
ISO EXP |
Carvedilol binds to and results in decreased activity of ADRA1A protein; Carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1A protein] results in increased phosphorylation of MAPK1 protein]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1A protein] results in increased phosphorylation of MAPK3 protein]; Carvedilol inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium] carvedilol results in decreased expression of ADRA1A mRNA |
CTD |
PMID:15306222 PMID:20668454 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Adra1b |
adrenoceptor alpha 1B |
multiple interactions |
ISO |
carvedilol binds to and results in decreased activity of ADRA1B protein; carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium]; carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1B protein] results in increased phosphorylation of MAPK1 protein]; carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1B protein] results in increased phosphorylation of MAPK3 protein]; carvedilol inhibits the reaction [[Phenylephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium] |
CTD |
PMID:15306222 |
|
NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919
|
|
G |
Adra1d |
adrenoceptor alpha 1D |
multiple interactions |
ISO |
carvedilol binds to and results in decreased activity of ADRA1D protein; carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium]; carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1D protein] results in increased phosphorylation of MAPK1 protein]; carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1D protein] results in increased phosphorylation of MAPK3 protein]; carvedilol inhibits the reaction [[Phenylephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium] |
CTD |
PMID:15306222 |
|
NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions affects binding increases expression increases phosphorylation increases activity affects response to substance |
ISO EXP |
[ADRB1 gene co-treated with ADRB2 gene] affects the susceptibility to Carvedilol; [Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP; ADRB1 protein polymorphism affects the reaction [[Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP]; ADRB1 protein polymorphism affects the susceptibility to [Carvedilol co-treated with Angiotensin Receptor Antagonists]; AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; ARRB1 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Carvedilol binds to and results in decreased activity of ADRB1 protein; Carvedilol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Carvedilol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Carvedilol inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Carvedilol inhibits the reaction [Isoproterenol results in increased activity of ADRB1 protein]; Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Carvedilol promotes the reaction [ADRB1 protein binds to ARRB1 protein]; Carvedilol promotes the reaction [ADRB1 protein binds to ARRB2 protein]; Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; CGP 20712A inhibits the reaction [[Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [Carvedilol results in increased activity of ADRB1 protein]; Guanine Nucleotides affects the reaction [Carvedilol binds to ADRB1 protein]; HBEGF protein inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] carvedilol binds to ADRB1 protein carvedilol results in increased expression of ADRB1 mRNA carvedilol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; carvedilol inhibits the reaction [Dihydroalprenolol binds to ADRB1 protein] [carvedilol results in increased phosphorylation of ADRB1 protein] which results in increased phosphorylation of EGFR protein; carvedilol results in increased phosphorylation of ADRB1 protein carvedilol results in increased activity of ADRB1 protein ADRB1 gene polymorphism affects the susceptibility to carvedilol; ADRB1 protein polymorphism affects the susceptibility to carvedilol |
CTD |
PMID:1378154 PMID:2462161 PMID:7908256 PMID:10372227 PMID:12535855 PMID:12761341 PMID:14502278 PMID:14730417 PMID:15060759 PMID:15306222 PMID:16475467 PMID:17200720 PMID:18075464 PMID:18787115 PMID:20643254 PMID:20668454 PMID:21216836 PMID:21395649 PMID:21516734 PMID:21599570 PMID:22192668 More...
|
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions increases phosphorylation affects binding increases expression increases uptake affects response to substance |
ISO EXP |
[ADRB1 gene co-treated with ADRB2 gene] affects the susceptibility to carvedilol; [carvedilol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [carvedilol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [carvedilol co-treated with ADRB2 protein] results in increased expression of GNAS protein; [carvedilol co-treated with ADRB2 protein] results in increased expression of GRK2 protein; carvedilol binds to and results in decreased activity of ADRB2 protein; carvedilol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; carvedilol inhibits the reaction [cyanopindolol binds to ADRB2 protein]; carvedilol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]; Guanine Nucleotides affects the reaction [carvedilol binds to ADRB2 protein]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein]; ICI 118551 inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]]; Propranolol inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]]; Propranolol inhibits the reaction [carvedilol results in increased phosphorylation of ADRB2 protein] carvedilol results in increased expression of ADRB2 mRNA carvedilol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; carvedilol inhibits the reaction [Dihydroalprenolol binds to ADRB2 protein] carvedilol inhibits the reaction [ADRB2 results in decreased susceptibility to Histamine]; carvedilol inhibits the reaction [ADRB2 results in increased expression of GRK2 protein] carvedilol results in increased uptake of ADRB2 protein ADRB2 gene SNP affects the susceptibility to carvedilol; ADRB2 protein polymorphism affects the susceptibility to carvedilol |
CTD |
PMID:1378154 PMID:2462161 PMID:10372227 PMID:10455254 PMID:12198331 PMID:12535855 PMID:12835612 PMID:14730417 PMID:15306222 PMID:16225854 PMID:17925438 PMID:19034036 PMID:19175363 PMID:19422106 PMID:20352314 PMID:20668454 PMID:21216836 PMID:21395649 PMID:21599570 More...
|
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions decreases expression affects response to substance |
ISO EXP |
carvedilol inhibits the reaction [cyanopindolol binds to ADRB3 protein] carvedilol results in decreased expression of ADRB3 mRNA ADRB3 affects the susceptibility to carvedilol |
CTD |
PMID:11159692 PMID:14730417 PMID:17440824 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Agt |
angiotensinogen |
multiple interactions decreases response to substance decreases expression |
EXP ISO |
[Losartan co-treated with Carvedilol] results in decreased susceptibility to AGT protein modified form; Carvedilol inhibits the reaction [AGT protein affects the localization of RAC1 protein]; Carvedilol inhibits the reaction [AGT protein results in increased abundance of Glycerol]; Carvedilol inhibits the reaction [AGT protein results in increased abundance of Norepinephrine]; Carvedilol inhibits the reaction [AGT protein results in increased abundance of Reactive Oxygen Species]; Carvedilol inhibits the reaction [Losartan results in decreased susceptibility to AGT protein modified form]; Losartan inhibits the reaction [Carvedilol results in decreased susceptibility to AGT protein modified form] carvedilol results in decreased susceptibility to AGT protein modified form carvedilol inhibits the reaction [AGT protein modified form promotes the reaction [Phenylephrine results in increased abundance of Inositol Phosphates]]; carvedilol inhibits the reaction [AGT protein modified form results in increased susceptibility to Phenylephrine] carvedilol results in decreased expression of AGT protein |
CTD |
PMID:12004934 PMID:12538430 PMID:15741261 PMID:16794485 PMID:16940222 PMID:19183357 PMID:21047287 PMID:21166975 More...
|
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
EXP ISO |
carvedilol results in increased phosphorylation of AKT1 protein |
CTD |
PMID:27288437 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
decreases expression |
ISO |
carvedilol results in decreased expression of APP protein modified form |
CTD |
PMID:20579773 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR125A mRNA; [carvedilol co-treated with ARRB1 protein] results in increased expression of MIR125B-1 mRNA; [carvedilol co-treated with ARRB1 protein] results in increased expression of MIR150 mRNA; [carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA; [carvedilol co-treated with ARRB1 protein] results in increased expression of MIR214 mRNA; ARRB1 protein promotes the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; carvedilol promotes the reaction [ADRB1 protein binds to ARRB1 protein]; carvedilol promotes the reaction [ARRB1 protein binds to DROSHA protein]; carvedilol promotes the reaction [ARRB1 protein binds to HNRNPA1 protein]; Colforsin inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]; GRK5 mutant form inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]; GRK6 mutant form inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]; Metoprolol inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA] ARRB1 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR125A mRNA]; ARRB1 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR125B-1 mRNA]; ARRB1 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR150 mRNA]; ARRB1 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR214 mRNA]; carvedilol promotes the reaction [ARRB1 protein binds to DROSHA protein]; carvedilol promotes the reaction [ARRB1 protein binds to HNRNPA1 protein] |
CTD |
PMID:18787115 PMID:24334028 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions affects localization |
ISO EXP |
ARRB2 protein promotes the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [carvedilol results in increased phosphorylation of MAPK1 protein]; ARRB2 protein promotes the reaction [carvedilol results in increased phosphorylation of MAPK3 protein]; carvedilol promotes the reaction [ADRB1 protein binds to ARRB2 protein]; carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]; ICI 118551 inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]]; Propranolol inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]] ARRB2 promotes the reaction [carvedilol results in increased uptake of Calcium] carvedilol affects the localization of ARRB2 protein |
CTD |
PMID:17925438 PMID:18787115 PMID:21078978 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions increases expression |
EXP |
carvedilol inhibits the reaction [Hydrogen Peroxide results in decreased expression of ATP2A2 mRNA]; carvedilol inhibits the reaction [Hydrogen Peroxide results in decreased expression of ATP2A2 protein] carvedilol results in increased expression of ATP2A2 mRNA |
CTD |
PMID:15670758 PMID:16026515 PMID:16162791 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Avp |
arginine vasopressin |
decreases expression multiple interactions |
ISO EXP |
carvedilol results in decreased expression of AVP protein carvedilol inhibits the reaction [AVP protein results in increased import of and results in increased abundance of Calcium] |
CTD |
PMID:12523682 PMID:14711191 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
EXP |
[[Oxygen deficiency co-treated with Glucose deficiency] results in increased susceptibility to Carvedilol] which results in decreased expression of BAK1 mRNA |
CTD |
PMID:29122578 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression decreases expression |
EXP ISO |
carvedilol inhibits the reaction [Doxorubicin results in increased expression of BAX mRNA]; carvedilol inhibits the reaction [Doxorubicin results in increased expression of BAX protein]; carvedilol inhibits the reaction [Potassium Dichromate results in increased expression of BAX protein] carvedilol inhibits the reaction [Cisplatin results in increased expression of BAX protein] carvedilol results in increased expression of BAX protein carvedilol results in decreased expression of BAX |
CTD |
PMID:12973927 PMID:15380674 PMID:20079142 PMID:24012798 PMID:25245570 PMID:26036690 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression affects expression |
EXP |
carvedilol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; carvedilol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; carvedilol inhibits the reaction [Potassium Dichromate results in decreased expression of BCL2 protein] carvedilol results in increased expression of BCL2 mRNA carvedilol affects the expression of BCL2 protein |
CTD |
PMID:15380674 PMID:16780994 PMID:16909474 PMID:22000973 PMID:25245570 PMID:26036690 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression |
EXP |
carvedilol results in increased expression of BCL2L1 protein |
CTD |
PMID:20079142 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Becn1 |
beclin 1 |
increases expression |
EXP |
carvedilol results in increased expression of BECN1 protein |
CTD |
PMID:20079142 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
EXP |
capsazepine inhibits the reaction [carvedilol results in increased secretion of [CALCA protein co-treated with CALCB protein]]; carvedilol results in increased secretion of [CALCA protein co-treated with CALCB protein] |
CTD |
PMID:14764656 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calcb |
calcitonin-related polypeptide, beta |
multiple interactions |
EXP |
capsazepine inhibits the reaction [carvedilol results in increased secretion of [CALCA protein co-treated with CALCB protein]]; carvedilol results in increased secretion of [CALCA protein co-treated with CALCB protein] |
CTD |
PMID:14764656 |
|
NCBI chr 1:168,965,383...168,970,259
Ensembl chr 1:168,966,465...168,970,125
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
multiple interactions |
EXP |
[Carvedilol co-treated with aliskiren] inhibits the reaction [Isoproterenol results in increased expression of CAMK2D protein]; Carvedilol inhibits the reaction [Isoproterenol results in increased expression of CAMK2D protein] |
CTD |
PMID:26982530 |
|
NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP ISO |
[Carvedilol co-treated with aliskiren] inhibits the reaction [Isoproterenol results in increased expression of CASP3 protein]; Carvedilol inhibits the reaction [Cisplatin results in increased activity of CASP3 protein]; Carvedilol inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; Carvedilol inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Carvedilol inhibits the reaction [Isoproterenol results in increased expression of CASP3 protein]; Carvedilol inhibits the reaction [Potassium Dichromate results in increased cleavage of CASP3 protein] carvedilol inhibits the reaction [Cisplatin results in increased cleavage of and results in increased activity of CASP3 protein] carvedilol inhibits the reaction [Epinephrine results in increased activity of CASP3 protein] |
CTD |
PMID:10728402 PMID:15380674 PMID:21044617 PMID:24012798 PMID:25245570 PMID:26036690 PMID:26982530 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions increases activity |
EXP |
Carvedilol inhibits the reaction [Arginine results in decreased activity of CAT protein]; Carvedilol inhibits the reaction [Chlorpromazine results in decreased expression of CAT protein]; Carvedilol inhibits the reaction [Haloperidol results in decreased expression of CAT protein]; Carvedilol inhibits the reaction [Isoproterenol results in decreased expression of and results in decreased activity of CAT protein]; Carvedilol inhibits the reaction [Potassium Dichromate results in decreased activity of CAT protein] carvedilol results in increased activity of CAT protein |
CTD |
PMID:12010767 PMID:16909474 PMID:25245570 PMID:25496245 PMID:32569593 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
EXP |
Carvedilol inhibits the reaction [Carbon Tetrachloride results in decreased expression of CDH1 protein] |
CTD |
PMID:30254303 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cfl1 |
cofilin 1 |
decreases expression |
EXP |
carvedilol results in decreased expression of CFL1 protein |
CTD |
PMID:20403466 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Ckb |
creatine kinase B |
multiple interactions |
EXP |
Carvedilol inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of [CKM protein binds to CKB protein]] |
CTD |
PMID:25496245 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions |
EXP |
[Carvedilol co-treated with aliskiren] inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of CKM protein]; Carvedilol inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of [CKM protein binds to CKB protein]]; Carvedilol inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of CKM protein] |
CTD |
PMID:25496245 PMID:26982530 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions decreases expression |
EXP |
carvedilol inhibits the reaction [[Sodium, Dietary co-treated with Dietary Fats] results in increased expression of COL1A1 mRNA]; carvedilol inhibits the reaction [Ethanol results in increased expression of COL1A1 mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA] carvedilol decreases expression of collagen I mRNA in kidney of high fat high sodium diet fed SHRSP/A3N rats Carvedilol results in decreased expression of COL1A1 mRNA; Carvedilol results in decreased expression of COL1A1 protein |
CTD RGD |
PMID:10722803 PMID:11181017 PMID:11682445 PMID:19575289 PMID:21216836 PMID:22413959 PMID:11682445 More...
|
RGD:30296650 |
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions decreases expression |
EXP |
carvedilol inhibits the reaction [[Sodium, Dietary co-treated with Dietary Fats] results in increased expression of COL3A1 mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA] carvedilol decreases expression of collagen III mRNA in kidney of high fat high sodium diet fed SHRSP/A3N rats carvedilol results in decreased expression of COL3A1 protein |
CTD RGD |
PMID:10722803 PMID:11181017 PMID:11682445 PMID:11682445 |
RGD:30296650 |
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Crp |
C-reactive protein |
decreases expression multiple interactions |
ISO EXP |
carvedilol results in decreased expression of CRP protein Carvedilol inhibits the reaction [Arginine results in increased expression of CRP protein] |
CTD |
PMID:15047035 PMID:32569593 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
carvedilol inhibits the reaction [CSF2 results in increased expression of IL10 mRNA]; carvedilol inhibits the reaction [CSF2 results in increased expression of IL10 protein] |
CTD |
PMID:12722941 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression |
EXP |
carvedilol results in increased expression of CYCS protein |
CTD |
PMID:18971572 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Carvedilol results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases activity |
ISO |
Carvedilol results in decreased activity of CYP1B1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
increases metabolic processing |
EXP |
CYP2C11 protein results in increased metabolism of carvedilol |
CTD |
PMID:29415952 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2d2 |
cytochrome P450, family 2, subfamily d, polypeptide 2 |
increases metabolic processing |
EXP |
CYP2D2 protein results in increased metabolism of carvedilol |
CTD |
PMID:29415952 |
|
NCBI chr 7:113,935,138...113,939,209
Ensembl chr 7:113,935,138...113,939,209
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects glucuronidation affects metabolic processing affects response to substance |
ISO |
CYP2D6 gene polymorphism affects the glucuronidation of carvedilol CYP2D6 gene polymorphism affects the metabolism of carvedilol; CYP2D6 protein polymorphism affects the metabolism of carvedilol CYP2D6 gene polymorphism affects the susceptibility to carvedilol |
CTD |
PMID:15001973 PMID:16595916 PMID:16849011 PMID:17329852 PMID:20643254 PMID:20686235 PMID:21599570 More...
|
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases metabolic processing |
EXP |
CYP3A2 protein results in increased metabolism of carvedilol |
CTD |
PMID:29415952 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
increases metabolic processing |
EXP |
CYP3A23-3A1 protein results in increased metabolism of Carvedilol |
CTD |
PMID:29415952 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
increases expression |
ISO |
Carvedilol results in increased expression of CYP7A1 protein |
CTD |
PMID:37632784 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
decreases expression |
ISO |
carvedilol results in decreased expression of DDIT4 mRNA |
CTD |
PMID:27288437 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Drosha |
drosha ribonuclease III |
multiple interactions |
ISO |
carvedilol promotes the reaction [ARRB1 protein binds to DROSHA protein] |
CTD |
PMID:24334028 |
|
NCBI chr 2:61,864,886...61,976,688
Ensembl chr 2:61,864,970...61,976,688
|
|
G |
Edn1 |
endothelin 1 |
decreases secretion decreases expression multiple interactions |
ISO EXP |
carvedilol results in decreased secretion of EDN1 protein carvedilol results in decreased expression of EDN1 mRNA carvedilol inhibits the reaction [EDN1 protein results in increased import of and results in increased abundance of Calcium] carvedilol results in decreased expression of EDN1 mRNA; carvedilol results in decreased expression of EDN1 protein carvedilol inhibits the reaction [Glucose results in increased expression of EDN1 mRNA]; carvedilol inhibits the reaction [Glucose results in increased expression of EDN1 protein] |
CTD |
PMID:9500873 PMID:11078433 PMID:14711191 PMID:16428915 PMID:18971572 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; ARRB1 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; HBEGF protein inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] [carvedilol results in increased phosphorylation of ADRB1 protein] which results in increased phosphorylation of EGFR protein |
CTD |
PMID:18787115 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
EXP |
[irbesartan co-treated with carvedilol] results in decreased expression of F3 mRNA; [irbesartan co-treated with carvedilol] results in decreased expression of F3 protein |
CTD |
PMID:21229253 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
carvedilol inhibits the reaction [Epinephrine results in increased expression of FAS protein] |
CTD |
PMID:10728402 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
carvedilol inhibits the reaction [Epinephrine results in increased expression of FASLG protein] |
CTD |
PMID:10728402 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
EXP |
carvedilol inhibits the reaction [Ethanol results in increased expression of FASN mRNA] |
CTD |
PMID:22413959 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
ISO |
carvedilol promotes the reaction [FKBP1B protein binds to RYR2 protein] |
CTD |
PMID:12743001 |
|
NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions decreases expression |
EXP |
carvedilol inhibits the reaction [[Sodium, Dietary co-treated with Dietary Fats] results in increased expression of FN1 mRNA]; carvedilol inhibits the reaction [Streptozocin results in increased expression of FN1 protein] carvedilol decreases expression of fibronectin mRNA in kidney of high fat high sodium diet fed SHRSP/A3N rats carvedilol results in decreased expression of FN1 protein |
CTD RGD |
PMID:11181017 PMID:11682445 PMID:12140129 PMID:11682445 |
RGD:30296650 |
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Gap43 |
growth associated protein 43 |
decreases expression |
EXP |
carvedilol results in decreased expression of GAP43 mRNA; carvedilol results in decreased expression of GAP43 protein |
CTD |
PMID:20359859 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gata4 |
GATA binding protein 4 |
decreases phosphorylation |
EXP |
carvedilol results in decreased phosphorylation of GATA4 protein |
CTD |
PMID:21472269 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression affects localization decreases phosphorylation increases phosphorylation decreases degradation |
ISO EXP |
carvedilol results in increased expression of GJA1 mRNA; carvedilol results in increased expression of GJA1 protein carvedilol affects the localization of GJA1 protein carvedilol results in decreased phosphorylation of GJA1 protein carvedilol results in increased phosphorylation of GJA1 protein carvedilol results in decreased degradation of GJA1 protein |
CTD |
PMID:16448880 PMID:16563290 PMID:17445419 PMID:18971572 PMID:19478468 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gja4 |
gap junction protein, alpha 4 |
increases expression |
EXP |
carvedilol results in increased expression of GJA4 protein |
CTD |
PMID:16448880 |
|
NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions increases expression |
ISO EXP |
[carvedilol co-treated with ADRB2 protein] results in increased expression of GNAS protein carvedilol results in increased expression of GNAS mRNA |
CTD |
PMID:10455254 PMID:20668454 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
EXP |
Carvedilol inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of GOT1 protein] |
CTD |
PMID:25496245 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpnmb |
glycoprotein nmb |
decreases expression |
EXP |
carvedilol results in decreased expression of GPNMB protein |
CTD |
PMID:20403466 |
|
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Carvedilol inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein]; Carvedilol inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of GPT protein] |
CTD |
PMID:25496245 PMID:30254303 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions decreases expression increases expression |
ISO |
[carvedilol co-treated with ADRB2 protein] results in increased expression of GRK2 protein carvedilol results in decreased expression of GRK2 protein carvedilol results in increased expression of GRK2 protein carvedilol inhibits the reaction [ADRB2 results in increased expression of GRK2 protein] |
CTD |
PMID:9788834 PMID:10455254 PMID:12198331 |
|
NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582
|
|
G |
Grk5 |
G protein-coupled receptor kinase 5 |
multiple interactions |
ISO |
GRK5 mutant form inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA] GRK5 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR125A mRNA]; GRK5 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR125B-1 mRNA]; GRK5 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR150 mRNA]; GRK5 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR214 mRNA] |
CTD |
PMID:24334028 |
|
NCBI chr 1:260,028,269...260,223,699
Ensembl chr 1:260,028,242...260,218,701
|
|
G |
Grk6 |
G protein-coupled receptor kinase 6 |
multiple interactions |
ISO |
GRK6 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR125A mRNA]; GRK6 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR125B-1 mRNA]; GRK6 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR150 mRNA]; GRK6 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR214 mRNA] GRK6 mutant form inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA] |
CTD |
PMID:24334028 |
|
NCBI chr17:9,177,018...9,192,813
Ensembl chr17:9,177,019...9,192,644
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions |
ISO |
HBEGF protein inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] |
CTD |
PMID:18787115 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
carvedilol results in increased expression of HMOX1 mRNA |
CTD |
PMID:11688356 PMID:12227681 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpa1 |
heterogeneous nuclear ribonucleoprotein A1 |
multiple interactions |
ISO |
carvedilol promotes the reaction [ARRB1 protein binds to HNRNPA1 protein] |
CTD |
PMID:24334028 |
|
NCBI chr 7:134,375,318...134,381,610
Ensembl chr 7:134,375,150...134,381,609
|
|
G |
Hpca |
hippocalcin |
affects localization |
EXP |
carvedilol affects the localization of HPCA protein |
CTD |
PMID:21078978 |
|
NCBI chr 5:141,455,616...141,466,252
Ensembl chr 5:141,455,613...141,463,841
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression |
EXP |
carvedilol results in increased expression of HSPH1 protein |
CTD |
PMID:20403466 |
|
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
carvedilol inhibits the reaction [Hemagglutinins results in increased expression of IFNG protein] |
CTD |
PMID:15229385 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
EXP |
carvedilol inhibits the reaction [Doxorubicin results in increased expression of IKBKB protein] |
CTD |
PMID:26036690 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
ISO EXP |
carvedilol inhibits the reaction [CSF2 results in increased expression of IL10 mRNA]; carvedilol inhibits the reaction [CSF2 results in increased expression of IL10 protein] carvedilol results in increased expression of IL10 mRNA; carvedilol results in increased expression of IL10 protein |
CTD |
PMID:12722941 PMID:16310260 PMID:18971572 PMID:20017808 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
carvedilol promotes the reaction [Hemagglutinins results in increased expression of [IL12A protein binds to IL12B protein]]; carvedilol promotes the reaction [Lipopolysaccharides results in increased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:15229385 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
carvedilol promotes the reaction [Hemagglutinins results in increased expression of [IL12A protein binds to IL12B protein]]; carvedilol promotes the reaction [Lipopolysaccharides results in increased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:15229385 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO EXP |
carvedilol results in decreased expression of IL1B mRNA carvedilol results in decreased expression of IL1B mRNA; carvedilol results in decreased expression of IL1B protein Carvedilol inhibits the reaction [Arginine results in increased expression of IL1B protein]; Carvedilol inhibits the reaction [Norepinephrine results in increased expression of IL1B mRNA] carvedilol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:10722803 PMID:14684360 PMID:15921778 PMID:16310260 PMID:20017808 PMID:32569593 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
increases expression |
EXP |
carvedilol results in increased expression of IL1RN protein |
CTD |
PMID:20017808 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
EXP |
carvedilol results in decreased expression of IL6 mRNA; carvedilol results in decreased expression of IL6 protein carvedilol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA] |
CTD |
PMID:10722803 PMID:11406463 PMID:16310260 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
decreases expression |
ISO |
carvedilol results in decreased expression of INS protein alternative form |
CTD |
PMID:16598518 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Jph2 |
junctophilin 2 |
increases expression |
ISO |
carvedilol results in increased expression of JPH2 protein |
CTD |
PMID:22375019 |
|
NCBI chr 3:151,994,768...152,058,941
Ensembl chr 3:151,994,778...152,058,904
|
|
G |
Kcna5 |
potassium voltage-gated channel subfamily A member 5 |
multiple interactions |
EXP |
carvedilol binds to and results in decreased activity of KCNA5 protein |
CTD |
PMID:22146582 |
|
NCBI chr 4:159,354,689...159,358,173
Ensembl chr 4:159,350,097...159,357,697
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity affects activity |
ISO |
carvedilol results in decreased activity of KCNH2 protein carvedilol affects the activity of KCNH2 protein |
CTD |
PMID:11164846 PMID:16314852 PMID:22020101 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
decreases activity |
ISO |
carvedilol results in decreased activity of KCNJ11 protein |
CTD |
PMID:16325804 |
|
NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Kcnj4 |
potassium inwardly-rectifying channel, subfamily J, member 4 |
multiple interactions |
ISO |
carvedilol binds to and results in decreased activity of KCNJ4 protein; Phosphatidylinositol Phosphates inhibits the reaction [carvedilol binds to and results in decreased activity of KCNJ4 protein] |
CTD |
PMID:21663737 |
|
NCBI chr 7:111,047,097...111,074,151
Ensembl chr 7:111,047,094...111,074,151
|
|
G |
Kcnk3 |
potassium two pore domain channel subfamily K member 3 |
decreases activity |
ISO |
carvedilol results in decreased activity of KCNK3 protein |
CTD |
PMID:21410455 |
|
NCBI chr 6:25,761,487...25,799,153
Ensembl chr 6:25,763,228...25,799,153
|
|
G |
Klf13 |
KLF transcription factor 13 |
multiple interactions |
EXP |
[[Oxygen deficiency co-treated with Glucose deficiency] results in increased susceptibility to Carvedilol] which results in decreased expression of KLF13 mRNA |
CTD |
PMID:29122578 |
|
NCBI chr 1:117,505,857...117,536,626
Ensembl chr 1:117,503,602...117,551,227
|
|
G |
Lox |
lysyl oxidase |
decreases expression |
EXP |
carvedilol results in decreased expression of LOX mRNA |
CTD |
PMID:21216836 |
|
NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
[Doxorubicin co-treated with carvedilol] results in increased phosphorylation of MAPK1 protein; carvedilol inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK1 protein] Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK1 protein] [Carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Carvedilol results in increased phosphorylation of MAPK1 protein]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1A protein] results in increased phosphorylation of MAPK1 protein]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1B protein] results in increased phosphorylation of MAPK1 protein]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1D protein] results in increased phosphorylation of MAPK1 protein]; Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ICI 118551 inhibits the reaction [[Carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] |
CTD |
PMID:11054474 PMID:15306222 PMID:16213474 PMID:17925438 PMID:18787115 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
EXP |
carvedilol inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:16213474 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
EXP ISO |
[Doxorubicin co-treated with carvedilol] results in increased phosphorylation of MAPK3 protein; carvedilol inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK3 protein] carvedilol results in increased phosphorylation of MAPK3 protein Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK3 protein] [Carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB1 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Carvedilol results in increased phosphorylation of MAPK3 protein]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1A protein] results in increased phosphorylation of MAPK3 protein]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1B protein] results in increased phosphorylation of MAPK3 protein]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1D protein] results in increased phosphorylation of MAPK3 protein]; Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; HBEGF protein inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ICI 118551 inhibits the reaction [[Carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:11054474 PMID:15306222 PMID:16213474 PMID:17925438 PMID:18787115 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mfge8 |
milk fat globule EGF and factor V/VIII domain containing |
decreases expression |
EXP |
carvedilol results in decreased expression of MFGE8 protein |
CTD |
PMID:20403466 |
|
NCBI chr 1:133,064,665...133,080,069
Ensembl chr 1:133,064,665...133,080,073
|
|
G |
Mir125a |
microRNA 125a |
multiple interactions increases expression |
ISO |
[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR125A mRNA ARRB1 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR125A mRNA]; GRK5 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR125A mRNA]; GRK6 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR125A mRNA] carvedilol results in increased expression of MIR125A mRNA |
CTD |
PMID:24334028 |
|
NCBI chr 1:58,677,626...58,677,710
Ensembl chr 1:58,677,626...58,677,710
|
|
G |
Mir125b1 |
microRNA 125b-1 |
multiple interactions increases expression |
ISO |
ARRB1 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR125B-1 mRNA]; GRK5 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR125B-1 mRNA]; GRK6 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR125B-1 mRNA] [carvedilol co-treated with ARRB1 protein] results in increased expression of MIR125B-1 mRNA |
CTD |
PMID:24334028 |
|
NCBI chr 8:41,952,966...41,953,052
Ensembl chr 8:41,952,966...41,953,052
|
|
G |
Mir125b2 |
microRNA 125b-2 |
increases expression |
ISO |
Carvedilol results in increased expression of MIR125B2 mRNA |
CTD |
PMID:29122578 |
|
NCBI chr11:16,245,620...16,245,707
|
|
G |
Mir150 |
microRNA 150 |
multiple interactions increases expression |
ISO |
[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR150 mRNA ARRB1 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR150 mRNA]; GRK5 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR150 mRNA]; GRK6 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR150 mRNA] |
CTD |
PMID:24334028 |
|
NCBI chr 1:95,605,024...95,605,108
Ensembl chr 1:95,605,024...95,605,108
|
|
G |
Mir190 |
microRNA 190 |
multiple interactions |
ISO |
[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA; Colforsin inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]; GRK5 mutant form inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]; GRK6 mutant form inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]; Metoprolol inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA] |
CTD |
PMID:24334028 |
|
NCBI chr 8:67,850,987...67,851,071
Ensembl chr 8:67,850,987...67,851,071
|
|
G |
Mir200a |
microRNA 200a |
multiple interactions |
EXP |
Carvedilol inhibits the reaction [Carbon Tetrachloride results in decreased expression of MIR200A mRNA] |
CTD |
PMID:30254303 |
|
NCBI chr 5:166,648,494...166,648,582
|
|
G |
Mir214 |
microRNA 214 |
multiple interactions increases expression |
ISO |
ARRB1 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR214 mRNA]; GRK5 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR214 mRNA]; GRK6 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR214 mRNA] [Carvedilol co-treated with ARRB1 protein] results in increased expression of MIR214 mRNA |
CTD |
PMID:24334028 |
|
NCBI chr13:74,588,374...74,588,481
Ensembl chr13:74,588,372...74,588,481
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases activity decreases expression |
EXP ISO |
carvedilol inhibits the reaction [Doxorubicin results in increased expression of MMP2 mRNA] carvedilol results in decreased activity of MMP2 protein carvedilol inhibits the reaction [TNF protein results in increased expression of MMP2 protein] carvedilol results in decreased expression of MMP2 |
CTD |
PMID:16213474 PMID:16310260 PMID:17964422 PMID:20452391 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp8 |
matrix metallopeptidase 8 |
decreases expression |
ISO |
carvedilol results in decreased expression of MMP8 mRNA |
CTD |
PMID:15921778 |
|
NCBI chr 8:4,724,009...4,733,864
Ensembl chr 8:4,724,029...4,733,520
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
affects activity decreases expression decreases activity multiple interactions |
ISO EXP |
carvedilol affects the activity of MMP9 protein carvedilol results in decreased expression of MMP9 mRNA carvedilol results in decreased activity of MMP9 protein carvedilol inhibits the reaction [TNF protein results in increased expression of MMP9 protein] carvedilol inhibits the reaction [Doxorubicin results in increased expression of MMP9 mRNA] |
CTD |
PMID:16213474 PMID:16310260 PMID:16574429 PMID:17964422 PMID:18971572 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO EXP |
carvedilol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of MPO protein] Carvedilol inhibits the reaction [Arginine results in increased expression of MPO protein] carvedilol inhibits the reaction [Calcimycin results in increased secretion of MPO protein]; carvedilol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of MPO protein]; carvedilol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MPO protein] |
CTD |
PMID:16601795 PMID:17159805 PMID:18987595 PMID:32569593 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Msn |
moesin |
decreases expression |
EXP |
carvedilol results in decreased expression of MSN protein |
CTD |
PMID:20403466 |
|
NCBI chr X:60,996,043...61,064,011
Ensembl chr X:60,995,951...61,065,628
|
|
G |
Mstn |
myostatin |
decreases expression |
EXP |
carvedilol results in decreased expression of MSTN mRNA; carvedilol results in decreased expression of MSTN protein |
CTD |
PMID:16968467 |
|
NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression affects expression |
EXP |
carvedilol results in decreased expression of MYC protein carvedilol affects the expression of MYC protein |
CTD |
PMID:21472269 PMID:22000973 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myl12a |
myosin light chain 12A |
decreases expression |
EXP |
carvedilol results in decreased expression of MYL12A protein |
CTD |
PMID:20403466 |
|
NCBI chr 9:110,891,970...110,899,655
Ensembl chr 9:110,873,959...110,916,580
|
|
G |
Nfatc4 |
nuclear factor of activated T-cells 4 |
increases phosphorylation |
EXP |
carvedilol results in increased phosphorylation of NFATC4 protein |
CTD |
PMID:21472269 |
|
NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO EXP |
Atenolol inhibits the reaction [carvedilol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; carvedilol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; carvedilol inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; carvedilol inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; carvedilol promotes the reaction [wortmannin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Prazosin inhibits the reaction [carvedilol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] carvedilol inhibits the reaction [Potassium Dichromate results in increased expression of NOS2 protein] |
CTD |
PMID:17159805 PMID:19439816 PMID:25245570 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases expression multiple interactions increases phosphorylation decreases expression |
EXP ISO |
carvedilol results in increased expression of NOS3 mRNA; carvedilol results in increased expression of NOS3 protein Carvedilol inhibits the reaction [Doxorubicin results in decreased phosphorylation of NOS3 protein] carvedilol results in increased phosphorylation of NOS3 protein carvedilol results in decreased expression of NOS3 mRNA |
CTD |
PMID:16741616 PMID:17559835 PMID:18971572 PMID:31066085 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
EXP |
carvedilol inhibits the reaction [Doxorubicin results in increased expression of NOX1 mRNA] |
CTD |
PMID:16213474 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Nphs1 |
NPHS1 adhesion molecule, nephrin |
increases expression |
EXP |
Carvedilol results in increased expression of NPHS1 |
CTD |
PMID:20452391 |
|
NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078
|
|
G |
Nppa |
natriuretic peptide A |
decreases expression increases expression decreases degradation multiple interactions |
ISO EXP |
carvedilol results in decreased expression of NPPA protein carvedilol results in increased expression of NPPA mRNA; carvedilol results in increased expression of NPPA protein carvedilol results in decreased expression of NPPA mRNA carvedilol results in decreased degradation of NPPA protein carvedilol inhibits the reaction [Norepinephrine results in increased expression of NPPA mRNA]; carvedilol promotes the reaction [NPPA protein results in increased abundance of Cyclic GMP] |
CTD |
PMID:1378157 PMID:9421401 PMID:10722803 PMID:11206715 PMID:21216836 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions decreases expression increases expression |
ISO EXP |
[carvedilol co-treated with temocapril hydrochloride co-treated with Spironolactone co-treated with Aspirin] affects the expression of NPPB protein carvedilol inhibits the reaction [Doxorubicin results in increased expression of NPPB protein] carvedilol results in decreased expression of NPPB protein carvedilol results in decreased expression of NPPB mRNA; carvedilol results in decreased expression of NPPB protein carvedilol results in increased expression of NPPB mRNA |
CTD |
PMID:11206715 PMID:19367012 PMID:19650993 PMID:19692266 PMID:20413026 PMID:21055277 PMID:21378469 PMID:26036690 More...
|
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Npr3 |
natriuretic peptide receptor 3 |
decreases expression |
EXP |
carvedilol results in decreased expression of NPR3 mRNA |
CTD |
PMID:9421401 PMID:11206715 |
|
NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
decreases expression |
ISO |
Carvedilol results in decreased expression of NR0B2 mRNA |
CTD |
PMID:37632784 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
increases expression |
ISO |
Carvedilol results in increased expression of NR1H4 mRNA |
CTD |
PMID:37632784 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
multiple interactions |
EXP |
carvedilol inhibits the reaction [Doxorubicin results in increased expression of OLR1 mRNA]; carvedilol inhibits the reaction [Doxorubicin results in increased expression of OLR1 protein]; carvedilol inhibits the reaction [Hydrogen Peroxide results in increased expression of OLR1 mRNA]; carvedilol inhibits the reaction [Hydrogen Peroxide results in increased expression of OLR1 protein] |
CTD |
PMID:16055083 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
carvedilol results in decreased susceptibility to [PDGFB protein binds to PDGFB protein] |
CTD |
PMID:11904532 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
multiple interactions |
EXP |
carvedilol inhibits the reaction [Norepinephrine results in increased activity of PGD mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased activity of PGD protein] |
CTD |
PMID:1378361 |
|
NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
carvedilol inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA] |
CTD |
PMID:22413959 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
EXP |
carvedilol results in increased expression of PPARGC1A mRNA |
CTD |
PMID:18971572 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkca |
protein kinase C, alpha |
decreases expression |
EXP |
carvedilol results in decreased expression of PRKCA protein |
CTD |
PMID:20668454 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Prkcd |
protein kinase C, delta |
decreases expression |
EXP |
carvedilol results in decreased expression of PRKCD protein |
CTD |
PMID:20668454 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkce |
protein kinase C, epsilon |
increases activity |
EXP |
carvedilol results in increased activity of PRKCE protein |
CTD |
PMID:16782078 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Ptafr |
platelet-activating factor receptor |
multiple interactions |
EXP |
Carvedilol inhibits the reaction [Arginine results in increased expression of PTAFR mRNA] |
CTD |
PMID:32569593 |
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases expression |
EXP |
carvedilol results in decreased expression of PTGS1 mRNA |
CTD |
PMID:16741616 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
EXP |
carvedilol inhibits the reaction [AGT protein affects the localization of RAC1 protein] |
CTD |
PMID:16940222 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Reg3b |
regenerating family member 3 beta |
multiple interactions |
EXP |
Carvedilol inhibits the reaction [Arginine results in increased expression of REG3B mRNA] |
CTD |
PMID:32569593 |
|
NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Carvedilol inhibits the reaction [Arginine results in increased expression of RELA protein]; Carvedilol inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of RELA protein]; Carvedilol inhibits the reaction [Doxorubicin results in increased expression of RELA protein]; Carvedilol inhibits the reaction [Potassium Dichromate affects the localization of RELA protein] |
CTD |
PMID:25245570 PMID:26036690 PMID:30254303 PMID:32569593 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
decreases expression multiple interactions |
ISO EXP |
carvedilol results in decreased expression of REN protein [aliskiren co-treated with Carvedilol] inhibits the reaction [Isoproterenol results in increased activity of REN protein]; Carvedilol inhibits the reaction [Isoproterenol results in increased activity of REN protein] |
CTD |
PMID:2454358 PMID:26982530 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Ryr2 |
ryanodine receptor 2 |
affects activity decreases activity increases expression multiple interactions increases activity |
ISO EXP |
carvedilol affects the activity of RYR2 protein; carvedilol analog affects the activity of RYR2 protein Carvedilol results in decreased activity of RYR2 protein carvedilol results in increased expression of RYR2 protein [Huang Qi co-treated with carvedilol] results in increased expression of RYR2 mRNA carvedilol promotes the reaction [Perindopril results in increased expression of RYR2 protein]; Perindopril promotes the reaction [carvedilol results in increased expression of RYR2 protein] carvedilol results in increased expression of RYR2 mRNA carvedilol results in increased activity of RYR2 protein carvedilol inhibits the reaction [Isoproterenol results in increased phosphorylation of RYR2 protein]; carvedilol promotes the reaction [FKBP1B protein binds to RYR2 protein] |
CTD |
PMID:12743001 PMID:19620082 PMID:21743453 PMID:21924056 PMID:37850394 |
|
NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142
|
|
G |
S100a10 |
S100 calcium binding protein A10 |
decreases expression |
EXP |
carvedilol results in decreased expression of S100A10 protein |
CTD |
PMID:20403466 |
|
NCBI chr 2:179,221,012...179,229,659
Ensembl chr 2:179,220,887...179,229,661
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
decreases expression |
EXP |
carvedilol results in decreased expression of S100A11 protein |
CTD |
PMID:20403466 |
|
NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
decreases expression |
EXP |
carvedilol results in decreased expression of S100A6 protein |
CTD |
PMID:20403466 |
|
NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180
|
|
G |
Serpinh1 |
serpin family H member 1 |
multiple interactions |
EXP |
carvedilol inhibits the reaction [Norepinephrine results in increased expression of SERPINH1 mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased expression of SERPINH1 protein] |
CTD |
PMID:10722803 |
|
NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression multiple interactions |
ISO |
Carvedilol results in decreased expression of SLC10A1 protein [Carvedilol co-treated with Albuterol] results in decreased expression of SLC10A1 protein; Carvedilol inhibits the reaction [Albuterol results in increased expression of SLC10A1 mRNA]; Carvedilol inhibits the reaction [Albuterol results in increased expression of SLC10A1 protein] |
CTD |
PMID:37632784 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
carvedilol inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Carvedilol inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Carvedilol inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Carvedilol inhibits the reaction [SLC22A2 protein results in increased uptake of Metformin] |
CTD |
PMID:19740083 PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO |
carvedilol inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; carvedilol inhibits the reaction [SLC22A3 protein results in increased uptake of Metformin] |
CTD |
PMID:21641380 PMID:21697722 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
G |
Slc22a4 |
solute carrier family 22 member 4 |
multiple interactions |
ISO |
carvedilol inhibits the reaction [SLC22A4 protein results in increased uptake of Tetraethylammonium] |
CTD |
PMID:21641380 |
|
NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720
|
|
G |
Smad7 |
SMAD family member 7 |
multiple interactions |
EXP |
Carvedilol inhibits the reaction [Carbon Tetrachloride results in decreased expression of SMAD7 protein] |
CTD |
PMID:30254303 |
|
NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
EXP |
Carvedilol inhibits the reaction [Isoproterenol results in decreased expression of and results in decreased activity of SOD1 protein] |
CTD |
PMID:25496245 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
EXP |
carvedilol inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein] |
CTD |
PMID:26036690 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
increases expression |
EXP ISO |
carvedilol results in increased expression of SOX2 mRNA |
CTD |
PMID:27288437 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
carvedilol inhibits the reaction [Ethanol results in increased expression of SREBF1 mRNA] |
CTD |
PMID:22413959 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
EXP |
Carvedilol inhibits the reaction [Arginine results in increased expression of STAT1 protein] |
CTD |
PMID:32569593 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Terf2 |
telomeric repeat binding factor 2 |
affects expression |
EXP |
carvedilol affects the expression of TERF2 protein |
CTD |
PMID:22000973 |
|
NCBI chr19:34,976,963...35,005,813
Ensembl chr19:34,977,471...35,005,819
|
|
G |
Tfpi |
tissue factor pathway inhibitor |
multiple interactions |
EXP |
[irbesartan co-treated with carvedilol] results in decreased expression of TFPI mRNA; [irbesartan co-treated with carvedilol] results in decreased expression of TFPI protein |
CTD |
PMID:21229253 |
|
NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression decreases expression multiple interactions |
ISO EXP |
carvedilol results in decreased expression of TGFB1 mRNA carvedilol decreases expression of TGFbeta mRNA in kidney of high fat high sodium diet fed SHRSP/A3N rats carvedilol results in decreased expression of TGFB1 mRNA; carvedilol results in decreased expression of TGFB1 protein Carvedilol inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]; Carvedilol inhibits the reaction [Ethanol results in increased expression of TGFB1 mRNA]; Carvedilol inhibits the reaction [Ethanol results in increased expression of TGFB1 protein]; Carvedilol inhibits the reaction [Sodium, Dietary results in increased expression of TGFB1 mRNA] |
CTD RGD |
PMID:11682445 PMID:11688356 PMID:12227681 PMID:15921778 PMID:16310260 PMID:19692266 PMID:22413959 PMID:30254303 PMID:11682445 More...
|
RGD:30296650 |
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions decreases expression |
EXP |
carvedilol inhibits the reaction [Ethanol results in increased expression of TH protein] carvedilol results in decreased expression of TH mRNA; carvedilol results in decreased expression of TH protein |
CTD |
PMID:20359859 PMID:22413959 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions decreases expression |
EXP |
carvedilol inhibits the reaction [Ethanol results in increased expression of TIMP1 mRNA]; carvedilol inhibits the reaction [Ethanol results in increased expression of TIMP1 protein] carvedilol results in decreased expression of TIMP1 mRNA |
CTD |
PMID:21216836 PMID:22413959 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; carvedilol inhibits the reaction [TNF protein results in increased expression of MMP2 protein]; carvedilol inhibits the reaction [TNF protein results in increased expression of MMP9 protein] carvedilol results in decreased expression of TNF mRNA; carvedilol results in decreased expression of TNF protein Carvedilol inhibits the reaction [Arginine results in increased expression of TNF protein]; Carvedilol inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; Carvedilol inhibits the reaction [Ethanol results in increased expression of TNF mRNA]; Carvedilol inhibits the reaction [Ethanol results in increased expression of TNF protein]; Carvedilol inhibits the reaction [Potassium Dichromate results in increased expression of TNF protein] |
CTD |
PMID:15229385 PMID:16310260 PMID:17964422 PMID:20017808 PMID:22413959 PMID:25245570 PMID:26036690 PMID:32569593 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
affects expression multiple interactions |
EXP |
carvedilol affects the expression of TP53 protein carvedilol inhibits the reaction [Potassium Dichromate results in increased expression of TP53 protein] |
CTD |
PMID:22000973 PMID:25245570 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
EXP |
carvedilol results in increased expression of TXN1 protein |
CTD |
PMID:20403466 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation affects metabolic processing affects glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of carvedilol UGT1A1 gene polymorphism affects the metabolism of carvedilol UGT1A1 gene polymorphism affects the glucuronidation of carvedilol |
CTD |
PMID:14744946 PMID:16849011 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases glucuronidation affects glucuronidation affects metabolic processing |
ISO |
UGT2B7 protein results in increased glucuronidation of carvedilol UGT2B7 gene polymorphism affects the glucuronidation of carvedilol UGT2B7 gene polymorphism affects the metabolism of carvedilol |
CTD |
PMID:14744946 PMID:16849011 PMID:17329852 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
G |
Vim |
vimentin |
multiple interactions |
EXP |
Carvedilol inhibits the reaction [Carbon Tetrachloride results in increased expression of VIM protein]; Carvedilol inhibits the reaction [Streptozocin results in increased expression of VIM protein] |
CTD |
PMID:12140129 PMID:30254303 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions affects binding increases activity |
ISO EXP |
[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Bupranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Carvedilol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Carvedilol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; CGP 12177 binds to and results in decreased activity of ADRB1 protein; CGP 12177 inhibits the reaction [cyanopindolol binds to ADRB1 protein]; CGP 12177 inhibits the reaction [Isoproterenol results in increased activity of ADRB1 protein]; CGP 20712A inhibits the reaction [[CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Metoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; N-(3-hydroxy-1-(naphthalen-1-yl)-1,8,11-trioxa-5-azatridecan-13-yl)-6-(2-(2-(4,4-difluoro-4,4a-dihydro-5-(thiophen-2-yl)-4-bora-3a,4a-diaza-s-indacene-3-yl)vinyl)phenoxyacetamido)hexanamide inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Nadolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Nebivolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Oxprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Pindolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Sotalol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP] Atenolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; carvedilol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; CGP 20712A inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Labetalol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Nebivolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Pindolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Propranolol inhibits the reaction [CGP 12177 binds to ADRB1 protein] |
CTD |
PMID:2462161 PMID:9593075 PMID:10217540 PMID:12535855 PMID:12761341 PMID:14730417 PMID:15060759 PMID:17628611 PMID:21870877 More...
|
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions affects binding |
ISO EXP |
[CGP 12177 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; carvedilol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; CGP 12177 binds to and results in decreased activity of ADRB2 protein; CGP 12177 inhibits the reaction [cyanopindolol binds to ADRB2 protein]; N-(3-hydroxy-1-(naphthalen-1-yl)-1,8,11-trioxa-5-azatridecan-13-yl)-6-(2-(2-(4,4-difluoro-4,4a-dihydro-5-(thiophen-2-yl)-4-bora-3a,4a-diaza-s-indacene-3-yl)vinyl)phenoxyacetamido)hexanamide inhibits the reaction [CGP 12177 binds to ADRB2 protein] Atenolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; carvedilol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; ICI 118551 inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Labetalol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Pindolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Propranolol inhibits the reaction [CGP 12177 binds to ADRB2 protein] |
CTD |
PMID:2462161 PMID:9593075 PMID:12535855 PMID:14730417 PMID:17628611 PMID:21870877 More...
|
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions affects binding increases activity affects response to substance |
ISO EXP |
[CGP 12177 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; CGP 12177 binds to and results in increased activity of ADRB3 protein; CGP 12177 inhibits the reaction [cyanopindolol binds to ADRB3 protein]; N-(3-hydroxy-1-(naphthalen-1-yl)-1,8,11-trioxa-5-azatridecan-13-yl)-6-(2-(2-(4,4-difluoro-4,4a-dihydro-5-(thiophen-2-yl)-4-bora-3a,4a-diaza-s-indacene-3-yl)vinyl)phenoxyacetamido)hexanamide inhibits the reaction [CGP 12177 binds to ADRB3 protein] CGP 12177 results in increased activity of ADRB3 protein ADRB3 affects the susceptibility to CGP 12177 3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [CGP 12177 results in increased activity of ADRB3 protein]; CGP 12177 binds to and results in increased activity of ADRB3 protein |
CTD |
PMID:7815362 PMID:8569714 PMID:10217540 PMID:10952688 PMID:11159692 PMID:11753577 PMID:14730417 PMID:15563584 PMID:21870877 More...
|
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions increases activity |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; Pertussis Toxin inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; U 0126 inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; wortmannin inhibits the reaction [CGP 12177 results in increased activity of CFTR protein] |
CTD |
PMID:15563584 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
EXP |
GH1 protein promotes the reaction [CGP 12177 results in increased metabolism of Lipids] |
CTD |
PMID:14981226 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
EXP |
CGP 12177 results in increased expression of LPL mRNA |
CTD |
PMID:9032464 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases activity |
ISO |
CGP 12177 results in increased activity of MAPK1 protein |
CTD |
PMID:15563584 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases activity |
ISO |
CGP 12177 results in increased activity of MAPK3 protein |
CTD |
PMID:15563584 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Usf1 |
upstream transcription factor 1 |
multiple interactions |
ISO |
USF1 gene polymorphism promotes the reaction [CGP 12177 results in increased metabolism of Lipids]; USF1 protein affects the reaction [CGP 12177 results in increased metabolism of Lipids] |
CTD |
PMID:15985485 |
|
NCBI chr13:83,845,230...83,854,875
Ensembl chr13:83,822,035...83,854,885
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
CGP 12177 results in increased expression of VEGFA mRNA |
CTD |
PMID:10788502 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
esmolol results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
increases expression |
ISO |
esmolol results in increased expression of BMP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Ereg |
epiregulin |
increases expression |
ISO |
esmolol results in increased expression of EREG mRNA |
CTD |
PMID:32816093 |
|
NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
esmolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein] |
CTD |
PMID:16627864 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
esmolol results in increased expression of IL1A mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
esmolol results in increased expression of IL1B mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il24 |
interleukin 24 |
increases expression |
ISO |
esmolol results in increased expression of IL24 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487
|
|
G |
Met |
MET proto-oncogene, receptor tyrosine kinase |
increases expression |
ISO |
esmolol results in increased expression of MET mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
|
|
G |
Pid1 |
phosphotyrosine interaction domain containing 1 |
increases expression |
ISO |
esmolol results in increased expression of PID1 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
esmolol results in increased expression of PTGS2 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ren |
renin |
multiple interactions |
ISO |
esmolol inhibits the reaction [Nitroprusside results in increased activity of REN protein] |
CTD |
PMID:2569849 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
increases expression |
ISO |
esmolol results in increased expression of SLPI mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
increases expression |
ISO |
esmolol results in increased expression of TNFAIP6 mRNA |
CTD |
PMID:32816093 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
[icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of AGT protein] |
CTD |
PMID:38027817 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
ISO EXP |
icatibant binds to and results in decreased activity of BDKRB2 protein; icatibant inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]; icatibant inhibits the reaction [KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] icatibant binds to and results in decreased activity of BDKRB2 protein; icatibant inhibits the reaction [KNG1 protein modified form binds to BDKRB2 protein] [icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Chondroitin Sulfates; [icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Streptozocin; [icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Vincristine; [icatibant results in decreased activity of BDKRB2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP]; [icatibant results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to benazepril; [icatibant results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Valsartan; icatibant binds to and results in decreased activity of BDKRB2 protein; icatibant inhibits the reaction [[KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Inositol Phosphates] |
CTD |
PMID:10666510 PMID:12727271 PMID:15140628 PMID:16982965 PMID:17347322 PMID:17989505 PMID:21436127 PMID:24975837 PMID:30685357 More...
|
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
EXP |
icatibant inhibits the reaction [KLK1 protein inhibits the reaction [Gentamicins results in increased expression of ICAM1 protein]] |
CTD |
PMID:16401625 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
[icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of IL6 protein] |
CTD |
PMID:38027817 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Klk1 |
kallikrein 1 |
multiple interactions |
EXP |
icatibant inhibits the reaction [KLK1 protein inhibits the reaction [Gentamicins results in increased expression of ICAM1 protein]]; icatibant inhibits the reaction [KLK1 protein inhibits the reaction [Gentamicins results in increased expression of TGFB1 protein]]; icatibant inhibits the reaction [KLK1 protein inhibits the reaction [Gentamicins results in increased phosphorylation of MAPK8 protein]]; icatibant inhibits the reaction [KLK1 protein results in increased abundance of Nitric Oxide] |
CTD |
PMID:16401625 |
|
NCBI chr 1:94,642,644...94,646,760
Ensembl chr 1:94,642,687...94,646,754
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions decreases activity |
ISO EXP |
icatibant inhibits the reaction [KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] icatibant inhibits the reaction [KNG1 protein modified form binds to BDKRB2 protein] icatibant results in decreased activity of KNG1 [icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of KNG1 protein]; icatibant inhibits the reaction [[KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Inositol Phosphates]; icatibant inhibits the reaction [KNG1 protein inhibits the reaction [Potassium Chloride results in increased secretion of TAC1 protein]]; icatibant inhibits the reaction [KNG1 results in increased expression of PTGS2 mRNA]; icatibant inhibits the reaction [KNG1 results in increased secretion of TAC1 protein] |
CTD |
PMID:1334751 PMID:15140628 PMID:15750287 PMID:16696851 PMID:17347322 PMID:22198006 PMID:30685357 PMID:38027817 More...
|
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases activity multiple interactions |
ISO |
icatibant results in increased activity of MAPK3 protein FR 173657 inhibits the reaction [icatibant results in increased activity of MAPK3 protein] |
CTD |
PMID:11139431 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
icatibant inhibits the reaction [KLK1 protein inhibits the reaction [Gentamicins results in increased phosphorylation of MAPK8 protein]] |
CTD |
PMID:16401625 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Plat |
plasminogen activator, tissue type |
decreases expression |
ISO |
icatibant results in decreased expression of PLAT protein |
CTD |
PMID:16321614 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
EXP |
icatibant inhibits the reaction [KNG1 results in increased expression of PTGS2 mRNA] |
CTD |
PMID:15750287 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
icatibant inhibits the reaction [KNG1 protein inhibits the reaction [Potassium Chloride results in increased secretion of TAC1 protein]]; icatibant inhibits the reaction [KNG1 results in increased secretion of TAC1 protein] |
CTD |
PMID:16696851 PMID:22198006 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
[icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]; icatibant inhibits the reaction [KLK1 protein inhibits the reaction [Gentamicins results in increased expression of TGFB1 protein]] |
CTD |
PMID:16401625 PMID:38027817 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
[icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of TNF protein] |
CTD |
PMID:38027817 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
ICI 118551 inhibits the reaction [Formoterol Fumarate results in decreased expression of ACTA2 protein] |
CTD |
PMID:21603974 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions |
ISO EXP |
[ICI 118551 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; ICI 118551 binds to and results in decreased activity of ADRB1 protein; ICI 118551 inhibits the reaction [cyanopindolol binds to ADRB1 protein] [Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 mRNA; [Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 protein; ICI 118551 inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein] |
CTD |
PMID:9260993 PMID:14730417 PMID:19719783 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions affects binding |
ISO EXP |
[ICI 118551 binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased abundance of Dinoprostone]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which results in decreased susceptibility to Nicotine; [ICI 118551 co-treated with ADRB2 protein] results in increased expression of GNAS protein; [ICI 118551 co-treated with ADRB2 protein] results in increased expression of GRK2 protein; ICI 118551 binds to and results in decreased activity of ADRB2 protein; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein]; ICI 118551 inhibits the reaction [[Carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein]; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [Albuterol results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [bitolterol results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [Carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]]; ICI 118551 inhibits the reaction [cimaterol results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [clenproperol results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [cyanopindolol binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [Fenoterol results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [Formoterol Fumarate affects the expression of ADRB2 mRNA]; ICI 118551 inhibits the reaction [Iodocyanopindolol binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Isoproterenol binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [Isoproterenol results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [olodaterol affects the expression of ADRB2 mRNA]; ICI 118551 inhibits the reaction [Terbutaline binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [Terbutaline results in increased activity of ADRB2 protein] [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Fenoterol affects the abundance of Norepinephrine]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] which affects the uptake of Levodopa; ICI 118551 binds to and results in decreased activity of ADRB2 protein; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Levodopa]; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Dopamine]; ICI 118551 inhibits the reaction [CGP 12177 binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Iodocyanopindolol binds to ADRB2 protein]; ICI 118551 inhibits the reaction [Terbutaline results in increased activity of ADRB2 protein] ICI 118551 inhibits the reaction [[BRL 37344 binds to and results in increased activity of ADRB2 protein] which results in increased uptake of Glucose]; ICI 118551 inhibits the reaction [[Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose]; ICI 118551 inhibits the reaction [ADRB2 results in decreased susceptibility to Histamine]; ICI 118551 inhibits the reaction [Isoproterenol results in increased activity of ADRB2 protein] |
CTD |
PMID:2462161 PMID:7969507 PMID:9260993 PMID:10344530 PMID:10372227 PMID:10455254 PMID:10894789 PMID:10952688 PMID:11096136 PMID:12198331 PMID:12535855 PMID:12608646 PMID:12920204 PMID:14730417 PMID:16036225 PMID:17003101 PMID:17369603 PMID:17925438 PMID:18552870 PMID:18820136 PMID:20054151 PMID:20590644 PMID:24705868 PMID:34601065 More...
|
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
ISO EXP |
[ICI 118551 binds to and results in decreased activity of ADRB3 protein] which results in decreased abundance of Cyclic AMP; ICI 118551 binds to and results in decreased activity of ADRB3 protein; ICI 118551 binds to and results in increased activity of ADRB3 protein; ICI 118551 inhibits the reaction [cyanopindolol binds to ADRB3 protein] [Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 mRNA; [Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 protein |
CTD |
PMID:1682311 PMID:14730417 PMID:19719783 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
ICI 118551 inhibits the reaction [Isoproterenol promotes the reaction [Dexamethasone results in increased expression of AGT protein]] |
CTD |
PMID:7843740 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Alpp |
alkaline phosphatase, placental |
multiple interactions |
ISO |
ICI 118551 inhibits the reaction [Isoproterenol results in increased expression of ALPP mRNA] |
CTD |
PMID:16036225 |
|
NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
ICI 118551 inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]] |
CTD |
PMID:17925438 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[ICI 118551 co-treated with Gemcitabine] results in increased expression of BAX protein |
CTD |
PMID:21570961 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[ICI 118551 co-treated with Gemcitabine] results in decreased expression of BCL2 protein |
CTD |
PMID:21570961 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions |
EXP |
capsazepine inhibits the reaction [ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein]]; ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein] |
CTD |
PMID:14764656 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calcb |
calcitonin-related polypeptide, beta |
multiple interactions |
EXP |
capsazepine inhibits the reaction [ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein]]; ICI 118551 results in increased secretion of [CALCA protein co-treated with CALCB protein] |
CTD |
PMID:14764656 |
|
NCBI chr 1:168,965,383...168,970,259
Ensembl chr 1:168,966,465...168,970,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
ICI 118551 inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:22167199 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
ICI 118551 inhibits the reaction [olodaterol results in decreased expression of EDN1 mRNA] |
CTD |
PMID:22796455 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Gnas |
GNAS complex locus |
multiple interactions increases expression |
ISO |
[ICI 118551 co-treated with ADRB2 protein] results in increased expression of GNAS protein ICI 118551 results in increased expression of GNAS protein |
CTD |
PMID:10455254 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
increases expression multiple interactions |
ISO |
ICI 118551 results in increased expression of GRK2 protein [ICI 118551 co-treated with ADRB2 protein] results in increased expression of GRK2 protein |
CTD |
PMID:10455254 |
|
NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
ICI 118551 inhibits the reaction [Isoproterenol results in increased expression of IL18 mRNA]; ICI 118551 inhibits the reaction [Isoproterenol results in increased expression of IL18 protein] |
CTD |
PMID:15178407 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
ICI 118551 inhibits the reaction [Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]] |
CTD |
PMID:16238794 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]]; ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; ICI 118551 inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; ICI 118551 inhibits the reaction [Terbutaline promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]] |
CTD |
PMID:9688336 PMID:10525314 PMID:11096136 PMID:12619890 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
ICI 118551 results in decreased activity of [KCNH2 protein binds to KCNH2 protein] ICI 118551 results in decreased activity of KCNH2 protein |
CTD |
PMID:15679475 PMID:16314852 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO EXP |
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK1 protein]] [Dobutamine co-treated with ICI 118551] results in increased activity of MAPK1 protein; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased activity of MAPK1 protein]] |
CTD |
PMID:11675405 PMID:12608646 PMID:17003101 PMID:17925438 PMID:19719783 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO EXP |
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of MAPK3 protein]] [Dobutamine co-treated with ICI 118551] results in increased activity of MAPK3 protein; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased activity of MAPK3 protein]] |
CTD |
PMID:11675405 PMID:12608646 PMID:17003101 PMID:17925438 PMID:19719783 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK9 protein |
CTD |
PMID:19719783 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression decreases secretion |
ISO |
ICI 118551 results in decreased expression of MMP2 mRNA; ICI 118551 results in decreased expression of MMP2 protein ICI 118551 results in decreased secretion of MMP2 protein |
CTD |
PMID:20424515 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression decreases secretion |
ISO |
ICI 118551 results in decreased expression of MMP9 mRNA; ICI 118551 results in decreased expression of MMP9 protein ICI 118551 results in decreased secretion of MMP9 protein |
CTD |
PMID:20424515 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression |
ISO |
ICI 118551 results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:17446185 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression multiple interactions |
ISO |
ICI 118551 results in decreased expression of PTGS2 mRNA; ICI 118551 results in decreased expression of PTGS2 protein [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2] |
CTD |
PMID:17003101 PMID:17369603 PMID:20424515 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
ICI 118551 inhibits the reaction [Albuterol results in decreased expression of RB1 protein] |
CTD |
PMID:16446544 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Ren |
renin |
multiple interactions |
ISO |
ICI 118551 inhibits the reaction [Epinephrine results in increased activity of REN protein] |
CTD |
PMID:6314140 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Shiga Toxin results in increased expression of TNF protein]] ICI 118551 inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ICI 118551 inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; ICI 118551 inhibits the reaction [Terbutaline inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]] |
CTD |
PMID:9688336 PMID:10525314 PMID:10857765 PMID:11096136 PMID:11675405 PMID:15081246 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
ICI 118551 results in decreased expression of VEGFA mRNA; ICI 118551 results in decreased expression of VEGFA protein |
CTD |
PMID:20424515 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions affects binding |
ISO EXP |
Albuterol inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; CGP 20712A inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Dobutamine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Epinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; ICI 89406 inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Isoproterenol inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Norepinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; soterenol inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Terbutaline inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein] Albuterol inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Dobutamine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Epinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; ICI 118551 inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; ICI 89406 inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Isoproterenol inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Norepinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; soterenol inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Terbutaline inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein] |
CTD |
PMID:8096834 PMID:9260993 PMID:10344530 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions affects binding |
ISO EXP |
ICI 118551 inhibits the reaction [Iodocyanopindolol binds to ADRB2 protein] |
CTD |
PMID:9260993 PMID:10344530 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Htr1b |
5-hydroxytryptamine receptor 1B |
affects binding multiple interactions |
EXP |
Iodocyanopindolol binds to HTR1B protein sarpogrelate inhibits the reaction [Iodocyanopindolol binds to HTR1B protein]; sarpogrelate metabolite inhibits the reaction [Iodocyanopindolol binds to HTR1B protein] |
CTD |
PMID:8937629 |
|
NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549
|
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases activity |
ISO |
Labetalol results in decreased activity of ABCB4 protein |
CTD |
PMID:28437613 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
increases activity |
ISO |
Labetalol results in increased activity of ACE2 protein |
CTD |
PMID:21859683 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
decreases activity affects binding increases activity multiple interactions |
ISO EXP |
Labetalol results in decreased activity of ADRB1 protein Labetalol binds to ADRB1 protein Labetalol results in increased activity of ADRB1 protein [Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP; CGP 20712A inhibits the reaction [[Labetalol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [Labetalol results in increased activity of ADRB1 protein] Labetalol binds to and results in decreased activity of ADRB1 protein; Labetalol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Labetalol inhibits the reaction [Dihydroalprenolol binds to ADRB1 protein] |
CTD |
PMID:2462161 PMID:2567112 PMID:11425575 PMID:11483288 PMID:12761341 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
decreases activity affects binding multiple interactions |
ISO EXP |
Labetalol results in decreased activity of ADRB2 protein Labetalol binds to ADRB2 protein [Labetalol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Labetalol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Labetalol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein Labetalol binds to and results in decreased activity of ADRB2 protein; Labetalol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Labetalol inhibits the reaction [Dihydroalprenolol binds to ADRB2 protein] |
CTD |
PMID:2462161 PMID:2567112 PMID:11425575 PMID:11483288 PMID:17925438 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Agt |
angiotensinogen |
decreases expression |
ISO |
Labetalol results in decreased expression of AGT protein |
CTD |
PMID:14627 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
ISO |
[Labetalol co-treated with Isoflurane] results in increased expression of AVP protein |
CTD |
PMID:1897344 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Labetalol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:17925438 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Labetalol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:17925438 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nppa |
natriuretic peptide A |
decreases activity |
ISO |
Labetalol results in decreased activity of NPPA protein |
CTD |
PMID:2524958 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Prl |
prolactin |
multiple interactions increases expression |
ISO |
carbidopa, levodopa drug combination inhibits the reaction [Labetalol results in increased expression of PRL protein] |
CTD |
PMID:7105431 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Ren |
renin |
multiple interactions decreases activity |
ISO |
[Labetalol co-treated with Isoflurane] results in increased expression of REN protein Labetalol results in decreased activity of REN protein |
CTD |
PMID:1897344 PMID:2524958 PMID:7013770 PMID:7988622 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions |
ISO |
[Uridine Diphosphate Glucuronic Acid co-treated with UGT1A1 protein] results in increased glucuronidation of Labetalol |
CTD |
PMID:18098064 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
multiple interactions |
ISO |
[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol; Fluconazole inhibits the reaction [[Uridine Diphosphate Glucuronic Acid co-treated with UGT2B7 protein] results in increased glucuronidation of Labetalol] |
CTD |
PMID:18098064 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
RT1-DMb |
RT1 class II, locus DMb |
affects expression |
ISO |
Levobunolol affects the expression of HLA-DMB mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:4,693,102...4,700,340
Ensembl chr20:4,693,103...4,700,340
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Metipranolol inhibits the reaction [Zinc results in increased expression of BCL2 protein]; Metipranolol inhibits the reaction [Zinc Sulfate results in increased expression of BCL2 protein] |
CTD |
PMID:16799065 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
Metipranolol inhibits the reaction [Zinc results in increased cleavage of CASP3 protein]; Metipranolol inhibits the reaction [Zinc Sulfate results in increased cleavage of CASP3 protein] |
CTD |
PMID:16799065 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Grk1 |
G protein-coupled receptor kinase 1 |
multiple interactions |
EXP |
Metipranolol inhibits the reaction [Zinc results in decreased expression of GRK1 protein]; Metipranolol inhibits the reaction [Zinc Sulfate results in decreased expression of GRK1 protein] |
CTD |
PMID:16799065 |
|
NCBI chr16:76,122,501...76,135,792
Ensembl chr16:76,123,842...76,135,792
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
Metipranolol inhibits the reaction [Zinc results in decreased expression of PARP1 protein]; Metipranolol inhibits the reaction [Zinc Sulfate results in decreased expression of PARP1 protein] |
CTD |
PMID:16799065 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
|
G |
Ace |
angiotensin I converting enzyme |
affects response to substance |
ISO |
ACE gene polymorphism affects the susceptibility to Metoprolol |
CTD |
PMID:20819590 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Adra2c |
adrenoceptor alpha 2C |
multiple interactions |
ISO |
[ADRB1 gene polymorphism co-treated with ADRA2C gene polymorphism] affects the susceptibility to Metoprolol |
CTD |
PMID:17496726 |
|
NCBI chr14:75,470,884...75,472,846
Ensembl chr14:75,471,143...75,472,846
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
decreases activity affects binding multiple interactions increases expression decreases methylation affects response to substance |
ISO EXP |
Metoprolol results in decreased activity of ADRB1 protein Metoprolol binds to ADRB1 protein [ADRB1 gene polymorphism co-treated with ADRA2C gene polymorphism] affects the susceptibility to Metoprolol; [Metoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; ADRB1 gene polymorphism affects the susceptibility to [Dobutamine co-treated with Metoprolol]; Metoprolol binds to and results in decreased activity of ADRB1 protein; Metoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Metoprolol inhibits the reaction [cyanopindolol binds to ADRB1 protein] Metoprolol results in increased expression of ADRB1 mRNA; Metoprolol results in increased expression of ADRB1 protein Metoprolol results in decreased methylation of ADRB1 promoter Metoprolol binds to and results in increased activity of ADRB1 protein; Metoprolol inhibits the reaction [Isoproterenol results in decreased expression of ADRB1 mRNA]; Metoprolol inhibits the reaction [Streptozocin results in decreased expression of ADRB1 protein] ADRB1 gene affects the susceptibility to Metoprolol; ADRB1 gene polymorphism affects the susceptibility to Metoprolol; ADRB1 protein polymorphism affects the susceptibility to Metoprolol |
CTD |
PMID:1312942 PMID:1389726 PMID:9593075 PMID:10372227 PMID:11562432 PMID:12844134 PMID:14730417 PMID:15060759 PMID:15864115 PMID:17200720 PMID:17496726 PMID:18703049 PMID:19094446 PMID:20590644 PMID:20675662 PMID:20821015 PMID:21311897 PMID:22165287 PMID:22192668 More...
|
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
affects binding multiple interactions increases expression affects response to substance |
EXP ISO |
Metoprolol binds to ADRB2 protein [Metoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Metoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; Metoprolol binds to and results in decreased activity of ADRB2 protein; Metoprolol inhibits the reaction [cyanopindolol binds to ADRB2 protein] Metoprolol promotes the reaction [Streptozocin results in increased expression of ADRB2 protein] Metoprolol results in increased expression of ADRB2 protein ADRB2 gene polymorphism affects the susceptibility to Metoprolol Metoprolol results in increased expression of ADRB2 mRNA |
CTD |
PMID:9593075 PMID:14730417 PMID:17671401 PMID:17925438 PMID:18703049 PMID:20675662 More...
|
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions increases expression |
EXP ISO |
Metoprolol promotes the reaction [Streptozocin results in increased expression of ADRB3 protein] Metoprolol inhibits the reaction [cyanopindolol binds to ADRB3 protein] Metoprolol results in increased expression of ADRB3 protein |
CTD |
PMID:14730417 PMID:18703049 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
EXP |
Metoprolol results in increased phosphorylation of AKT1 protein |
CTD |
PMID:18703049 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
Metoprolol inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA] |
CTD |
PMID:24334028 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Arrb2 |
arrestin, beta 2 |
affects response to substance |
ISO |
ARRB2 protein affects the susceptibility to Metoprolol |
CTD |
PMID:22888001 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atp2a2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
increases expression |
EXP |
Metoprolol results in increased expression of ATP2A2 mRNA |
CTD |
PMID:16162791 |
|
NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Isoproterenol results in increased expression of BCL2L1 protein] |
CTD |
PMID:12738230 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Casp3 |
caspase 3 |
increases cleavage |
ISO |
Metoprolol results in increased cleavage of CASP3 protein |
CTD |
PMID:19106745 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases cleavage |
ISO |
Metoprolol results in increased cleavage of CASP9 protein |
CTD |
PMID:19106745 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
EXP ISO |
Metoprolol results in increased expression of CCN2 mRNA |
CTD |
PMID:22888001 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO EXP |
Metoprolol results in increased expression of COL1A1 mRNA |
CTD |
PMID:22888001 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
increases expression |
ISO |
Metoprolol results in increased expression of COL3A1 mRNA |
CTD |
PMID:30809271 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
EXP |
Metoprolol results in increased expression of CPT1A protein |
CTD |
PMID:19233164 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt1b |
carnitine palmitoyltransferase 1B |
multiple interactions decreases expression |
EXP |
Metoprolol inhibits the reaction [[[PPARGC1A protein results in increased expression of MEF2A mRNA] co-treated with [PPARGC1A protein results in increased expression of PPARA mRNA]] results in increased expression of CPT1B protein]; Metoprolol inhibits the reaction [MEF2A protein binds to CPT1B promoter]; Metoprolol inhibits the reaction [PPARGC1A protein binds to CPT1B promoter] Metoprolol results in decreased expression of CPT1B protein |
CTD |
PMID:19233164 |
|
NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404
|
|
G |
Cyb5a |
cytochrome b5 type A |
affects metabolic processing |
ISO |
CYB5A affects the metabolism of Metoprolol |
CTD |
PMID:20430864 |
|
NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535 Ensembl chr18:78,202,342...78,258,535
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects response to substance increases metabolic processing multiple interactions affects metabolic processing |
ISO |
CYP2D6 gene affects the susceptibility to Metoprolol; CYP2D6 gene polymorphism affects the susceptibility to Metoprolol CYP2D6 protein results in increased metabolism of Metoprolol [Paroxetine results in decreased activity of CYP2D6 protein] which results in decreased degradation of Metoprolol; [Paroxetine results in decreased activity of CYP2D6 protein] which results in increased susceptibility to Metoprolol; [Terbinafine results in decreased activity of CYP2D6 protein] inhibits the reaction [CYP2D6 protein results in increased metabolism of Metoprolol]; CYP2D6 gene polymorphism affects the reaction [Amiodarone results in increased abundance of Metoprolol]; Hydroxychloroquine inhibits the reaction [CYP2D6 protein results in increased metabolism of Metoprolol]; YM 758 inhibits the reaction [CYP2D6 protein results in increased metabolism of Metoprolol] CYP2D6 protein affects the metabolism of Metoprolol; CYP2D6 protein polymorphism affects the metabolism of Metoprolol |
CTD |
PMID:10470702 PMID:10848718 PMID:11823760 PMID:12172215 PMID:12464242 PMID:15286053 PMID:15327588 PMID:15541258 PMID:18648788 PMID:18784654 PMID:18979093 PMID:19094446 PMID:19230594 PMID:24894748 More...
|
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases hydroxylation |
ISO |
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Metoprolol] |
CTD |
PMID:30087611 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ece1 |
endothelin converting enzyme 1 |
decreases expression |
ISO |
Metoprolol results in decreased expression of ECE1 mRNA |
CTD |
PMID:9607404 |
|
NCBI chr 5:150,077,679...150,179,375
Ensembl chr 5:150,077,644...150,179,371
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Norepinephrine results in increased expression of EDN1 mRNA] |
CTD |
PMID:11435416 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Fkbp1b |
FKBP prolyl isomerase 1B |
multiple interactions |
ISO |
Metoprolol promotes the reaction [FKBP1B protein binds to RYR2 protein] |
CTD |
PMID:12743001 |
|
NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]] |
CTD |
PMID:15179140 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxo3 |
forkhead box O3 |
decreases expression |
EXP |
Metoprolol results in decreased expression of FOXO3 protein |
CTD |
PMID:18703049 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Norepinephrine results in increased activity of G6PD protein] |
CTD |
PMID:1378361 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gata4 |
GATA binding protein 4 |
decreases phosphorylation |
EXP |
Metoprolol results in decreased phosphorylation of GATA4 protein |
CTD |
PMID:21472269 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression affects localization multiple interactions |
EXP |
Metoprolol results in increased expression of GJA1 protein Metoprolol affects the localization of GJA1 protein [Isoproterenol co-treated with Metoprolol] results in increased expression of GJA1 protein |
CTD |
PMID:17445419 PMID:20215810 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Grk4 |
G protein-coupled receptor kinase 4 |
affects response to substance |
ISO |
GRK4 gene SNP affects the susceptibility to Metoprolol |
CTD |
PMID:19119263 |
|
NCBI chr14:75,998,554...76,080,808
Ensembl chr14:76,006,218...76,080,693
|
|
G |
Grk5 |
G protein-coupled receptor kinase 5 |
affects response to substance |
ISO |
GRK5 protein affects the susceptibility to Metoprolol |
CTD |
PMID:22888001 |
|
NCBI chr 1:260,028,269...260,223,699
Ensembl chr 1:260,028,242...260,218,701
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 mRNA]; Metoprolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein]; Metoprolol inhibits the reaction [Xamoterol results in increased expression of HMOX1 protein] |
CTD |
PMID:15179140 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression increases secretion |
ISO |
Metoprolol results in increased expression of IL1A mRNA Metoprolol results in increased secretion of IL1A protein |
CTD |
PMID:17467819 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA] |
CTD |
PMID:11406463 PMID:12619890 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jph2 |
junctophilin 2 |
increases expression |
ISO |
Metoprolol results in increased expression of JPH2 protein |
CTD |
PMID:22375019 |
|
NCBI chr 3:151,994,768...152,058,941
Ensembl chr 3:151,994,778...152,058,904
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]] |
CTD |
PMID:15179140 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]] |
CTD |
PMID:15179140 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions decreases activity |
ISO |
Metoprolol results in decreased activity of [KCNH2 protein binds to KCNH2 protein] Metoprolol results in decreased activity of KCNH2 protein |
CTD |
PMID:15679475 PMID:16314852 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [[[PPARGC1A protein results in increased expression of MEF2A mRNA] co-treated with [PPARGC1A protein results in increased expression of PPARA mRNA]] results in increased expression of CPT1B protein]; Metoprolol inhibits the reaction [MEF2A protein binds to CPT1B promoter] |
CTD |
PMID:19233164 |
|
NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948
|
|
G |
Mir190 |
microRNA 190 |
multiple interactions |
ISO |
Metoprolol inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA] |
CTD |
PMID:24334028 |
|
NCBI chr 8:67,850,987...67,851,071
Ensembl chr 8:67,850,987...67,851,071
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression decreases secretion multiple interactions |
ISO EXP |
Metoprolol results in decreased expression of MMP2 mRNA; Metoprolol results in decreased expression of MMP2 protein Metoprolol results in decreased secretion of MMP2 protein Metoprolol inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA] |
CTD |
PMID:15326086 PMID:20424515 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression decreases secretion |
ISO |
Metoprolol results in decreased expression of MMP9 mRNA; Metoprolol results in decreased expression of MMP9 protein Metoprolol results in decreased secretion of MMP9 protein |
CTD |
PMID:20424515 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
EXP |
Metoprolol results in decreased expression of MYC protein |
CTD |
PMID:21472269 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
EXP |
Metoprolol promotes the reaction [Phenylephrine results in increased expression of MYH7 mRNA] |
CTD |
PMID:17592507 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Nfatc4 |
nuclear factor of activated T-cells 4 |
increases phosphorylation |
EXP |
Metoprolol results in increased phosphorylation of NFATC4 protein |
CTD |
PMID:21472269 |
|
NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [[Ramipril co-treated with Sodium Chloride deficiency] results in increased expression of NOS1 protein]; Metoprolol inhibits the reaction [Ramipril promotes the reaction [Sodium Chloride deficiency results in increased expression of NOS1 mRNA]]; Metoprolol inhibits the reaction [Sodium Chloride deficiency results in increased expression of NOS1 mRNA] |
CTD |
PMID:11832429 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Streptozocin results in increased expression of NOS2 protein] |
CTD |
PMID:18703049 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases expression |
EXP |
Metoprolol results in decreased expression of NOS3 protein |
CTD |
PMID:18703049 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions decreases expression |
EXP |
Metoprolol promotes the reaction [Phenylephrine results in increased expression of NPPA mRNA] Metoprolol results in decreased expression of NPPA mRNA |
CTD |
PMID:17592507 PMID:20353484 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
decreases expression |
EXP |
Metoprolol results in decreased expression of NPPB mRNA; Metoprolol results in decreased expression of NPPB protein |
CTD |
PMID:11181074 PMID:20353484 PMID:30310171 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
decreases metabolic processing |
ISO |
NR1I3 gene mutant form results in decreased metabolism of Metoprolol |
CTD |
PMID:27434302 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
multiple interactions |
ISO |
Metoprolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein] |
CTD |
PMID:10353628 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Penk |
proenkephalin |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Isoproterenol results in increased expression of PENK mRNA] |
CTD |
PMID:1363325 |
|
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [[[PPARGC1A protein results in increased expression of MEF2A mRNA] co-treated with [PPARGC1A protein results in increased expression of PPARA mRNA]] results in increased expression of CPT1B protein] |
CTD |
PMID:19233164 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [[[PPARGC1A protein results in increased expression of MEF2A mRNA] co-treated with [PPARGC1A protein results in increased expression of PPARA mRNA]] results in increased expression of CPT1B protein]; Metoprolol inhibits the reaction [PPARGC1A protein binds to CPT1B promoter]; Metoprolol promotes the reaction [USF2 protein binds to PPARGC1A protein] |
CTD |
PMID:19233164 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ppp3ca |
protein phosphatase 3 catalytic subunit alpha |
decreases expression |
EXP |
Metoprolol results in decreased expression of PPP3CA protein |
CTD |
PMID:30310171 |
|
NCBI chr 2:225,165,981...225,440,978
Ensembl chr 2:225,165,766...225,438,974
|
|
G |
Prdx3 |
peroxiredoxin 3 |
increases expression |
EXP |
Metoprolol results in increased expression of PRDX3 protein |
CTD |
PMID:30310171 |
|
NCBI chr 1:260,001,642...260,014,064
Ensembl chr 1:260,001,637...260,014,111
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression decreases expression |
EXP ISO |
Metoprolol inhibits the reaction [Isoflurane results in increased expression of PTGS2 mRNA]; Metoprolol inhibits the reaction [Oxygen deficiency results in increased expression of PTGS2 mRNA] Metoprolol results in increased expression of PTGS2 mRNA Metoprolol results in decreased expression of PTGS2 mRNA; Metoprolol results in decreased expression of PTGS2 protein |
CTD |
PMID:17467819 PMID:20424515 PMID:21615343 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ren |
renin |
decreases expression |
ISO EXP |
Metoprolol results in decreased expression of REN protein Metoprolol results in decreased expression of REN mRNA |
CTD |
PMID:2454358 PMID:8203557 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases expression |
EXP |
Metoprolol results in increased expression of RPS6KB1 mRNA |
CTD |
PMID:28099878 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Ryr2 |
ryanodine receptor 2 |
multiple interactions increases activity |
ISO |
Metoprolol promotes the reaction [FKBP1B protein binds to RYR2 protein] Metoprolol results in increased activity of RYR2 protein |
CTD |
PMID:12743001 |
|
NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142
|
|
G |
Sgcd |
sarcoglycan, delta |
affects response to substance |
ISO |
SGCD affects the susceptibility to Metoprolol |
CTD |
PMID:20675662 |
|
NCBI chr10:31,346,480...32,328,364
Ensembl chr10:31,280,511...31,724,840
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
Metoprolol inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Metoprolol inhibits the reaction [SLC22A2 protein results in increased uptake of Metformin] |
CTD |
PMID:19740083 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Spn |
sialophorin |
decreases response to substance |
ISO |
SPN protein results in decreased susceptibility to Metoprolol |
CTD |
PMID:18711009 |
|
NCBI chr 1:181,746,937...181,759,564
Ensembl chr 1:181,746,429...181,759,628
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
EXP |
Metoprolol results in increased expression of TGFB1 mRNA |
CTD |
PMID:22888001 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thbs1 |
thrombospondin 1 |
decreases expression |
EXP |
Metoprolol results in decreased expression of THBS1 mRNA |
CTD |
PMID:20353484 |
|
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Thbs4 |
thrombospondin 4 |
decreases expression |
EXP |
Metoprolol results in decreased expression of THBS4 mRNA |
CTD |
PMID:20353484 |
|
NCBI chr 2:23,983,158...24,025,289
Ensembl chr 2:23,983,158...24,026,313
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Norepinephrine results in increased expression of TIMP2 mRNA] |
CTD |
PMID:15326086 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Metoprolol inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]] |
CTD |
PMID:15081246 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Usf2 |
upstream transcription factor 2, c-fos interacting |
multiple interactions increases expression |
EXP |
Metoprolol promotes the reaction [USF2 protein binds to PPARGC1A protein] Metoprolol results in increased expression of USF2 protein |
CTD |
PMID:19233164 |
|
NCBI chr 1:86,174,703...86,185,942
Ensembl chr 1:86,174,703...86,185,617
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Metoprolol results in decreased expression of VEGFA mRNA; Metoprolol results in decreased expression of VEGFA protein |
CTD |
PMID:20424515 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions |
ISO |
Nadolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:15060759 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
[Nadolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP |
CTD |
PMID:17925438 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[Nadolol co-treated with Mifepristone] promotes the reaction [methyldithiocarbamate promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]] |
CTD |
PMID:16321413 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
[Nadolol co-treated with Mifepristone] inhibits the reaction [methyldithiocarbamate inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]] |
CTD |
PMID:16321413 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
Nadolol inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:21641380 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions affects binding |
ISO EXP |
Nebivolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Nebivolol inhibits the reaction [cyanopindolol binds to ADRB1 protein] Nebivolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Nebivolol inhibits the reaction [Dihydroalprenolol binds to ADRB1 protein] Nebivolol binds to ADRB1 protein |
CTD |
PMID:2462161 PMID:12535855 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
Nebivolol inhibits the reaction [AGT protein affects the localization of NCF2 protein]; Nebivolol inhibits the reaction [AGT protein results in decreased expression of VASP protein]; Nebivolol inhibits the reaction [AGT protein results in increased expression of CYBA mRNA]; Nebivolol inhibits the reaction [AGT protein results in increased expression of CYBB mRNA]; Nebivolol inhibits the reaction [AGT protein results in increased expression of NCF1 mRNA]; Nebivolol inhibits the reaction [AGT protein results in increased expression of NCF2 protein]; Nebivolol inhibits the reaction [AGT protein results in increased expression of NOX1 protein]; Nebivolol inhibits the reaction [AGT protein results in increased expression of RAC1 protein] |
CTD |
PMID:16940222 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
EXP |
Nebivolol promotes the reaction [Alendronate inhibits the reaction [Methylprednisolone results in increased secretion of ALPL protein]] |
CTD |
PMID:30291735 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Ar |
androgen receptor |
increases expression multiple interactions |
EXP ISO |
Nebivolol results in increased expression of AR protein Nebivolol binds to and results in decreased activity of AR protein |
CTD |
PMID:19962728 PMID:25752796 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
EXP |
[Nebivolol co-treated with Alendronate] inhibits the reaction [Methylprednisolone results in decreased secretion of BGLAP protein] |
CTD |
PMID:30291735 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
Nebivolol promotes the reaction [Alendronate inhibits the reaction [Methylprednisolone results in decreased activity of CAT protein]] |
CTD |
PMID:30291735 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression decreases secretion |
ISO |
Nebivolol results in decreased expression of CCL2 mRNA Nebivolol results in decreased secretion of CCL2 protein |
CTD |
PMID:17310107 PMID:17467819 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
EXP |
Nebivolol inhibits the reaction [AGT protein results in increased expression of CYBA mRNA] |
CTD |
PMID:16940222 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
EXP |
Nebivolol inhibits the reaction [AGT protein results in increased expression of CYBB mRNA] |
CTD |
PMID:16940222 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Ddah2 |
DDAH family member 2, ADMA-independent |
multiple interactions increases expression increases activity |
ISO |
Dactinomycin inhibits the reaction [Nebivolol results in increased expression of DDAH2 mRNA] Nebivolol results in increased expression of DDAH2 mRNA; Nebivolol results in increased expression of DDAH2 protein Nebivolol results in increased activity of DDAH2 protein |
CTD |
PMID:17977009 |
|
NCBI chr20:3,761,460...3,764,718
Ensembl chr20:3,761,465...3,764,511
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
increases expression |
ISO |
Nebivolol results in increased expression of DHCR24 mRNA |
CTD |
PMID:17467819 |
|
NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Edn1 |
endothelin 1 |
decreases secretion decreases expression |
ISO |
Nebivolol results in decreased secretion of EDN1 protein Nebivolol results in decreased expression of EDN1 mRNA |
CTD |
PMID:11078433 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Nebivolol binds to and results in decreased activity of ESR1 protein |
CTD |
PMID:25752796 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
affects activity multiple interactions |
ISO |
Nebivolol affects the activity of ESR2 protein Nebivolol binds to and results in decreased activity of ESR2 protein |
CTD |
PMID:19330906 PMID:25752796 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression |
ISO |
Nebivolol results in decreased expression of ICAM1 mRNA |
CTD |
PMID:17310107 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1a |
interleukin 1 alpha |
decreases expression |
ISO |
Nebivolol results in decreased expression of IL1A mRNA |
CTD |
PMID:17467819 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
EXP |
Nebivolol inhibits the reaction [AGT protein results in increased expression of NCF1 mRNA] |
CTD |
PMID:16940222 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
EXP |
Nebivolol inhibits the reaction [AGT protein affects the localization of NCF2 protein]; Nebivolol inhibits the reaction [AGT protein results in increased expression of NCF2 protein] |
CTD |
PMID:16940222 |
|
NCBI chr13:64,955,622...64,986,144
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression |
ISO |
Nebivolol results in increased expression of NFE2L2 |
CTD |
PMID:23886954 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos3 |
nitric oxide synthase 3 |
increases activity increases expression multiple interactions |
ISO EXP |
Nebivolol results in increased activity of NOS3 protein Nebivolol results in increased expression of NOS3 protein [Nebivolol co-treated with Flutamide] results in increased expression of NOS3 protein |
CTD |
PMID:17977009 PMID:19962728 PMID:23886954 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
EXP |
Nebivolol inhibits the reaction [AGT protein results in increased expression of NOX1 protein] |
CTD |
PMID:16940222 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
Nebivolol results in increased expression of NPPB protein |
CTD |
PMID:18192850 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
decreases expression |
ISO |
Nebivolol results in decreased expression of PDGFA mRNA |
CTD |
PMID:17467819 |
|
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression |
ISO |
Nebivolol results in decreased expression of PDGFB mRNA |
CTD |
PMID:17310107 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Nebivolol binds to and results in decreased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions increases expression |
ISO |
3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [Nebivolol results in increased expression of PPARGC1A protein] |
CTD |
PMID:23886954 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
Nebivolol results in decreased expression of PTGS2 mRNA |
CTD |
PMID:17467819 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rac1 |
Rac family small GTPase 1 |
multiple interactions |
EXP |
Nebivolol inhibits the reaction [AGT protein results in increased expression of RAC1 protein] |
CTD |
PMID:16940222 |
|
NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251
|
|
G |
Ren |
renin |
multiple interactions |
EXP |
Nebivolol inhibits the reaction [Nitric Oxide deficiency results in increased expression of REN protein] |
CTD |
PMID:12806161 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Sele |
selectin E |
decreases expression |
ISO |
Nebivolol results in decreased expression of SELE mRNA |
CTD |
PMID:17310107 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Selp |
selectin P |
decreases expression |
ISO |
Nebivolol results in decreased expression of SELP mRNA |
CTD |
PMID:17310107 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions increases expression |
ISO |
3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [Nebivolol results in increased expression of SIRT3 protein] |
CTD |
PMID:23886954 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions affects expression |
ISO EXP |
3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [Nebivolol affects the expression of SOD2 protein] Nebivolol inhibits the reaction [Daunorubicin results in decreased secretion of SOD2 protein] |
CTD |
PMID:18194856 PMID:23886954 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tfam |
transcription factor A, mitochondrial |
increases expression |
ISO |
Nebivolol results in increased expression of TFAM |
CTD |
PMID:23886954 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
Nebivolol binds to and results in decreased activity of THRA protein |
CTD |
PMID:25752796 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
decreases expression |
ISO |
Nebivolol results in decreased expression of TNFAIP6 mRNA |
CTD |
PMID:17467819 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
multiple interactions |
EXP |
Nebivolol inhibits the reaction [Daunorubicin results in increased expression of TNNT2 protein] |
CTD |
PMID:18194856 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
multiple interactions |
EXP |
Nebivolol inhibits the reaction [AGT protein results in decreased expression of VASP protein]; Nebivolol inhibits the reaction [Phorbol Esters results in decreased phosphorylation of VASP protein] |
CTD |
PMID:16940222 |
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
decreases expression |
ISO |
Nebivolol results in decreased expression of VCAM1 mRNA |
CTD |
PMID:17310107 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vipr1 |
vasoactive intestinal peptide receptor 1 |
increases expression |
ISO |
Nebivolol results in increased expression of VIPR1 mRNA |
CTD |
PMID:17467819 |
|
NCBI chr 8:121,303,739...121,339,587
Ensembl chr 8:121,310,248...121,339,585
|
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
increases expression affects binding increases activity multiple interactions |
ISO EXP |
Pindolol results in increased expression of ADRB1 protein Pindolol binds to ADRB1 protein Pindolol results in increased activity of ADRB1 protein [Pindolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; CGP 20712A affects the reaction [Pindolol results in increased activity of ADRB1 protein]; Pindolol binds to and results in decreased activity of ADRB1 protein; Pindolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Pindolol inhibits the reaction [cyanopindolol binds to ADRB1 protein] Pindolol binds to and results in decreased activity of ADRB1 protein; Pindolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Pindolol inhibits the reaction [Dihydroalprenolol binds to ADRB1 protein] |
CTD |
PMID:2175014 PMID:2462161 PMID:2888869 PMID:12761341 PMID:14730417 PMID:15060759 More...
|
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
decreases expression affects binding multiple interactions |
ISO EXP |
Pindolol results in decreased expression of ADRB2 protein Pindolol binds to ADRB2 protein Pindolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Pindolol inhibits the reaction [Dihydroalprenolol binds to ADRB2 protein] [Pindolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Pindolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Pindolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Pindolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; Pindolol binds to and results in decreased activity of ADRB2 protein; Pindolol inhibits the reaction [cyanopindolol binds to ADRB2 protein] |
CTD |
PMID:2175014 PMID:2462161 PMID:14730417 PMID:17925438 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions |
EXP ISO |
Pindolol binds to and results in increased activity of ADRB3 protein [Pindolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Pindolol binds to and results in increased activity of ADRB3 protein; Pindolol inhibits the reaction [cyanopindolol binds to ADRB3 protein] |
CTD |
PMID:1682311 PMID:7815362 PMID:14730417 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
Pindolol inhibits the reaction [REN protein results in increased cleavage of AGT protein] |
CTD |
PMID:7104148 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
EXP |
Pindolol binds to and affects the activity of HTR1A protein; Pindolol binds to and results in decreased activity of HTR1A protein |
CTD |
PMID:2207497 PMID:9809859 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Htr1b |
5-hydroxytryptamine receptor 1B |
affects binding |
EXP |
Pindolol binds to HTR1B protein |
CTD |
PMID:11888550 |
|
NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Pindolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:17925438 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Pindolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:17925438 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO EXP |
Pindolol inhibits the reaction [Buspirone results in increased secretion of PRL protein] |
CTD |
PMID:18194152 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Ren |
renin |
multiple interactions decreases expression decreases activity |
ISO |
Pindolol inhibits the reaction [REN protein results in increased cleavage of AGT protein] Pindolol results in decreased expression of REN protein Pindolol results in decreased activity of REN protein |
CTD |
PMID:791319 PMID:973972 PMID:7104148 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
[Practolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Practolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Practolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:17925438 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Practolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:17925438 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Practolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:17925438 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Ren |
renin |
decreases activity |
EXP |
Practolol results in decreased activity of REN protein |
CTD |
PMID:6110712 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
|
G |
Aanat |
aralkylamine N-acetyltransferase |
multiple interactions |
EXP |
Propranolol inhibits the reaction [Parathion results in increased expression of AANAT protein] |
CTD |
PMID:10685507 |
|
NCBI chr10:101,827,072...101,831,805
Ensembl chr10:101,827,301...101,831,801
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
ISO |
Propranolol results in increased expression of ABCB1 mRNA Propranolol inhibits the reaction [ABCB1 protein results in increased transport of Digoxin] |
CTD |
PMID:15276086 PMID:16671962 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Ada |
adenosine deaminase |
multiple interactions |
EXP |
Propranolol promotes the reaction [ADA protein results in decreased susceptibility to Norepinephrine] |
CTD |
PMID:7949234 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adm |
adrenomedullin |
decreases response to substance |
EXP |
Propranolol results in decreased susceptibility to ADM protein |
CTD |
PMID:9845272 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
multiple interactions affects binding increases expression increases activity affects response to substance |
EXP ISO |
Propranolol binds to and results in decreased activity of ADRB1 protein; Propranolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Propranolol inhibits the reaction [Dihydroalprenolol binds to ADRB1 protein] Propranolol binds to ADRB1 protein Propranolol results in increased expression of ADRB1 mRNA Propranolol results in increased activity of ADRB1 protein [Propranolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Propranolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; Propranolol binds to and results in decreased activity of ADRB1 protein; Propranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; Propranolol inhibits the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; Propranolol inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Propranolol inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; Propranolol inhibits the reaction [Isoproterenol results in increased activity of ADRB1 protein]; Propranolol inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRB1 protein] ADRB1 protein polymorphism affects the susceptibility to Propranolol |
CTD |
PMID:2462161 PMID:6141285 PMID:9593075 PMID:10372227 PMID:10952688 PMID:11425575 PMID:11483288 PMID:12761341 PMID:14502278 PMID:14730417 PMID:15060759 PMID:15627480 PMID:17200720 PMID:18787115 PMID:20668454 More...
|
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
decreases expression multiple interactions affects binding increases expression |
ISO EXP |
Propranolol results in decreased expression of ADRB2 mRNA [Propranolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Propranolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Propranolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Propranolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Propranolol co-treated with ADRB2 protein] results in increased expression of GNAS protein; [Propranolol co-treated with ADRB2 protein] results in increased expression of GRK2 protein; Propranolol binds to and results in decreased activity of ADRB2 protein; Propranolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; Propranolol inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]]; Propranolol inhibits the reaction [carvedilol results in increased phosphorylation of ADRB2 protein]; Propranolol inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Propranolol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; Propranolol inhibits the reaction [Isoproterenol binds to and results in increased activity of ADRB2 protein]; Propranolol inhibits the reaction [Norepinephrine binds to ADRB2 protein]; Propranolol inhibits the reaction [Terbutaline binds to and results in increased activity of ADRB2 protein] Propranolol results in increased expression of ADRB2 mRNA Propranolol binds to and results in decreased activity of ADRB2 protein; Propranolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Propranolol inhibits the reaction [Dihydroalprenolol binds to ADRB2 protein] |
CTD |
PMID:2169833 PMID:2462161 PMID:2897299 PMID:6141285 PMID:9593075 PMID:10372227 PMID:10455254 PMID:10952688 PMID:11425575 PMID:11483288 PMID:12920204 PMID:14730417 PMID:15603589 PMID:17925438 PMID:20668454 PMID:24929186 More...
|
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Adrb3 |
adrenoceptor beta 3 |
multiple interactions affects response to substance |
ISO |
Propranolol inhibits the reaction [cyanopindolol binds to ADRB3 protein] ADRB3 affects the susceptibility to Propranolol |
CTD |
PMID:11159692 PMID:14730417 |
|
NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552
|
|
G |
Agt |
angiotensinogen |
multiple interactions decreases expression |
ISO |
Propranolol inhibits the reaction [Isoproterenol results in increased expression of AGT protein]; Propranolol inhibits the reaction [REN protein results in increased cleavage of AGT protein] Propranolol inhibits the reaction [AGT protein modified form results in increased abundance of Superoxides]; Propranolol inhibits the reaction [Isoproterenol promotes the reaction [Dexamethasone results in increased expression of AGT protein]] Propranolol results in decreased expression of AGT protein |
CTD |
PMID:14627 PMID:1653766 PMID:7104148 PMID:7843740 PMID:12606818 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
Propranolol results in decreased phosphorylation of AKT1 protein ANGPT2 protein inhibits the reaction [Propranolol results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:30130526 PMID:31838054 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
1-oleoyl-2-acetoyl-sn-glycerol inhibits the reaction [Propranolol inhibits the reaction [Calcimycin results in increased activity of and results in increased localization of ALOX5 protein]]; Propranolol inhibits the reaction [Calcimycin results in increased activity of and results in increased localization of ALOX5 protein] |
CTD |
PMID:18218859 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Amy2a3 |
amylase 2a3 |
multiple interactions |
EXP |
Propranolol inhibits the reaction [Isoproterenol results in increased secretion of and results in increased activity of AMY1A protein] |
CTD |
PMID:21173550 |
|
NCBI chr 2:201,317,916...201,326,487
Ensembl chr 2:201,317,920...201,326,532
|
|
G |
Angpt2 |
angiopoietin 2 |
decreases expression multiple interactions |
ISO |
Propranolol results in decreased expression of ANGPT2 mRNA; Propranolol results in decreased expression of ANGPT2 protein ANGPT2 protein inhibits the reaction [Propranolol results in decreased expression of BCL2 protein]; ANGPT2 protein inhibits the reaction [Propranolol results in decreased expression of MKI67 protein]; ANGPT2 protein inhibits the reaction [Propranolol results in decreased phosphorylation of AKT1 protein]; ANGPT2 protein inhibits the reaction [Propranolol results in increased expression of BAX protein] |
CTD |
PMID:31838054 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Arf6 |
ADP-ribosylation factor 6 |
affects localization |
ISO |
Propranolol affects the localization of ARF6 protein |
CTD |
PMID:16280360 |
|
NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
Propranolol inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]] |
CTD |
PMID:17925438 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
EXP |
Propranolol inhibits the reaction [Terbutaline results in increased expression of ATP1A1 mRNA] |
CTD |
PMID:9700104 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression multiple interactions increases expression |
EXP ISO |
Propranolol results in decreased expression of BAX mRNA Propranolol inhibits the reaction [Arsenic Trioxide results in increased expression of BAX protein] Fat Emulsions, Intravenous inhibits the reaction [Propranolol results in increased expression of BAX protein] ANGPT2 protein inhibits the reaction [Propranolol results in increased expression of BAX protein] |
CTD |
PMID:11218852 PMID:31838054 PMID:35738838 PMID:36707890 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions decreases expression |
EXP ISO |
Propranolol results in increased expression of BCL2 mRNA Propranolol inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein] Propranolol results in decreased expression of BCL2 protein ANGPT2 protein inhibits the reaction [Propranolol results in decreased expression of BCL2 protein] |
CTD |
PMID:11218852 PMID:31838054 PMID:36707890 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
ISO |
BDKRB2 affects the susceptibility to [Propranolol co-treated with Atropine] |
CTD |
PMID:10614985 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
multiple interactions affects activity |
EXP |
Propranolol promotes the reaction [CALCA protein affects the susceptibility to Norepinephrine] Propranolol affects the activity of CALCA protein |
CTD |
PMID:7906887 PMID:8058111 PMID:10075105 PMID:18055875 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases activity decreases expression |
ISO EXP |
Propranolol results in increased cleavage of CASP3 protein Acetylcysteine inhibits the reaction [Propranolol results in increased cleavage of CASP3 protein]; Fat Emulsions, Intravenous inhibits the reaction [Propranolol results in increased cleavage of CASP3 protein] Propranolol results in increased activity of CASP3 protein Palmitic Acid promotes the reaction [Propranolol results in increased activity of CASP3 protein] Propranolol results in decreased expression of CASP3 mRNA |
CTD |
PMID:11218852 PMID:19106745 PMID:22700542 PMID:35738838 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
Propranolol results in increased activity of CASP7 protein |
CTD |
PMID:22700542 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
increases cleavage multiple interactions |
ISO EXP |
Propranolol results in increased cleavage of CASP9 protein Fat Emulsions, Intravenous inhibits the reaction [Propranolol results in increased cleavage of CASP9 protein] |
CTD |
PMID:19106745 PMID:35738838 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Propranolol inhibits the reaction [Epinephrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein]] Propranolol inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]]; Propranolol promotes the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein] |
CTD |
PMID:9863660 PMID:12538206 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
ISO |
Propranolol inhibits the reaction [Isoproterenol results in decreased expression of COL2A1 mRNA]; Propranolol inhibits the reaction [Isoproterenol results in decreased expression of COL2A1 protein] |
CTD |
PMID:21177286 |
|
NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Propranolol inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of CREB1 protein] |
CTD |
PMID:15522277 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
EXP |
Propranolol affects the reaction [Norepinephrine affects the expression of and affects the secretion of CRH protein]; Propranolol inhibits the reaction [acephate results in increased expression of CRH mRNA]; Propranolol inhibits the reaction [acephate results in increased secretion of CRH protein]; Propranolol inhibits the reaction [methamidophos results in increased expression of CRH mRNA]; Propranolol inhibits the reaction [methamidophos results in increased secretion of CRH protein] |
CTD |
PMID:3497798 PMID:12039681 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression multiple interactions |
ISO EXP |
Propranolol results in increased expression of CYP1A1 protein Propranolol inhibits the reaction [Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein]]; Propranolol inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein]] Propranolol promotes the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:15618653 PMID:15627480 PMID:15710352 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects metabolic processing increases expression multiple interactions |
ISO EXP |
CYP1A2 protein affects the metabolism of Propranolol Propranolol results in increased expression of CYP1A2 protein Propranolol inhibits the reaction [Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein]]; Propranolol inhibits the reaction [Isoproterenol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein]] |
CTD |
PMID:15286053 PMID:15618653 PMID:15710352 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
Propranolol inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1B1 mRNA] |
CTD |
PMID:22167199 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
increases oxidation affects metabolic processing |
ISO |
CYP2C19 protein results in increased oxidation of Propranolol CYP2C19 protein affects the metabolism of Propranolol |
CTD |
PMID:15286053 PMID:19853591 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d2 |
cytochrome P450, family 2, subfamily d, polypeptide 2 |
multiple interactions |
EXP |
Propranolol inhibits the reaction [CYP2D2 protein results in increased metabolism of 3-(2-(N,N-diethyl-N-methylammonium)ethyl)-7-methoxy-4-methylcoumarin] |
CTD |
PMID:19858067 |
|
NCBI chr 7:113,935,138...113,939,209
Ensembl chr 7:113,935,138...113,939,209
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing increases oxidation affects metabolic processing |
ISO |
CYP2D6 protein results in increased metabolism of Propranolol CYP2D6 protein results in increased oxidation of Propranolol CYP2D6 protein affects the metabolism of Propranolol |
CTD |
PMID:12464242 PMID:15286053 PMID:19853591 PMID:21184751 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases oxidation |
ISO |
CYP3A4 protein results in increased oxidation of Propranolol |
CTD |
PMID:19853591 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Dll4 |
delta like canonical Notch ligand 4 |
decreases expression multiple interactions |
ISO |
Propranolol results in decreased expression of DLL4 protein DLL4 protein inhibits the reaction [Propranolol results in decreased expression of MMP2 protein]; DLL4 protein inhibits the reaction [Propranolol results in decreased expression of MMP9 protein] |
CTD |
PMID:30130526 |
|
NCBI chr 3:106,317,114...106,327,004
Ensembl chr 3:106,316,986...106,326,931
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; Propranolol inhibits the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]] |
CTD |
PMID:18787115 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
Propranolol inhibits the reaction [Isoproterenol results in increased expression of EGR1 protein] |
CTD |
PMID:15621046 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions |
EXP |
[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of ELK1 protein; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of ELK1 protein] |
CTD |
PMID:11880281 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
EXP |
Propranolol results in decreased expression of FAS mRNA |
CTD |
PMID:11218852 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases expression |
EXP |
Propranolol results in increased expression of FGF1 mRNA |
CTD |
PMID:15264218 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fmo2 |
flavin containing dimethylaniline monoxygenase 2 |
increases oxidation |
ISO |
FMO2 protein results in increased oxidation of Propranolol |
CTD |
PMID:26062974 |
|
NCBI chr13:75,221,149...75,244,377
Ensembl chr13:75,224,402...75,244,308
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
[Norepinephrine co-treated with Propranolol] results in increased expression of FN1 protein |
CTD |
PMID:11821714 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
Propranolol inhibits the reaction [3-(N-phenylamino)-1,2-propanediol 1,2-dioleoyl ester analog results in increased expression of FOS mRNA]; Propranolol inhibits the reaction [Ethanol results in increased expression of FOS protein]; Propranolol inhibits the reaction [Haloperidol results in increased expression of FOS protein]; Propranolol inhibits the reaction [Isoproterenol results in increased expression of FOS] Propranolol results in increased expression of FOS protein |
CTD |
PMID:7905536 PMID:9748542 PMID:15501433 PMID:22236039 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gad1 |
glutamate decarboxylase 1 |
multiple interactions |
EXP |
Propranolol inhibits the reaction [Amphetamine inhibits the reaction [3-acetylpyridine results in increased expression of GAD1 mRNA]]; Propranolol inhibits the reaction [Clenbuterol inhibits the reaction [3-acetylpyridine results in increased expression of GAD1 mRNA]] |
CTD |
PMID:8774452 |
|
NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
affects localization |
EXP |
Propranolol affects the localization of GJA1 protein |
CTD |
PMID:17445419 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gk |
glycerol kinase |
decreases activity |
EXP |
Propranolol results in decreased activity of GK protein |
CTD |
PMID:12736183 |
|
NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631
|
|
G |
Gnas |
GNAS complex locus |
increases expression multiple interactions |
EXP ISO |
Propranolol results in increased expression of GNAS mRNA [Propranolol co-treated with ADRB2 protein] results in increased expression of GNAS protein |
CTD |
PMID:10455254 PMID:20668454 |
|
NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262 Ensembl chr 3:163,071,417...163,127,262
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions increases expression decreases expression |
ISO |
[Propranolol co-treated with ADRB2 protein] results in increased expression of GRK2 protein Propranolol results in increased expression of GRK2 protein Propranolol results in decreased expression of GRK2 protein |
CTD |
PMID:9788834 PMID:10455254 |
|
NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
decreases phosphorylation |
EXP |
Propranolol results in decreased phosphorylation of GSK3B protein |
CTD |
PMID:22982863 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Propranolol inhibits the reaction [Isoproterenol results in increased expression of HMOX1 protein]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of HMOX1 mRNA] |
CTD |
PMID:19483313 PMID:24929186 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hpca |
hippocalcin |
affects localization |
EXP |
Propranolol affects the localization of HPCA protein |
CTD |
PMID:21078978 |
|
NCBI chr 5:141,455,616...141,466,252
Ensembl chr 5:141,455,613...141,463,841
|
|
G |
Htr1b |
5-hydroxytryptamine receptor 1B |
affects binding |
EXP |
Propranolol binds to HTR1B protein |
CTD |
PMID:11888550 |
|
NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:82,517,360...82,534,549
|
|
G |
Il10 |
interleukin 10 |
increases expression |
EXP |
Propranolol results in increased expression of IL10 mRNA |
CTD |
PMID:16908771 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases secretion |
ISO EXP |
Propranolol promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] Propranolol results in decreased secretion of IL1B protein |
CTD |
PMID:11854442 PMID:16386803 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Propranolol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; Propranolol inhibits the reaction [Ozone results in increased expression of IL6 mRNA]; Propranolol inhibits the reaction [Ozone results in increased expression of IL6 protein] |
CTD |
PMID:12619890 < |